Previous evidence-based guidelines on the management of intra-abdominal infection (IAI) were published by the Surgical Infection Society (SIS) in 1992, 2002, and 2010. At the time the most recent guideline was released, the plan was to update the guideline every five years to ensure the timeliness and appropriateness of the recommendations.
Methods:
Based on the previous guidelines, the task force outlined a number of topics related to the treatment of patients with IAI and then developed key questions on these various topics. All questions were approached using general and specific literature searches, focusing on articles and other information published since 2008. These publications and additional materials published before 2008 were reviewed by the task force as a whole or by individual subgroups as to relevance to individual questions. Recommendations were developed by a process of iterative consensus, with all task force members voting to accept or reject each recommendation. Grading was based on the GRADE (Grades of Recommendation Assessment, Development, and Evaluation) system; the quality of the evidence was graded as high, moderate, or weak, and the strength of the recommendation was graded as strong or weak. Review of the document was performed by members of the SIS who were not on the task force. After responses were made to all critiques, the document was approved as an official guideline of the SIS by the Executive Council.
Results:
This guideline summarizes the current recommendations developed by the task force on the treatment of patients who have IAI. Evidence-based recommendations have been made regarding risk assessment in individual patients; source control; the timing, selection, and duration of antimicrobial therapy; and suggested approaches to patients who fail initial therapy. Additional recommendations related to the treatment of pediatric patients with IAI have been included.
Summary:
The current recommendations of the SIS regarding the treatment of patients with IAI are provided in this guideline.
Get full access to this article
View all access options for this article.
References
1.
BohnenJM, SolomkinJS, DellingerEP, et al.Guidelines for clinical care: Anti-infective agents for intra-abdominal infection. A Surgical Infection Society policy statement. Arch Surg, 1992; 127:83–89.
2.
MazuskiJE, SawyerRG, NathensAB, et al.The Surgical Infection Society guidelines on antimicrobial therapy for intra-abdominal infections: An executive summary. Surg Infect (Larchmt), 2002; 3:161–173.
3.
MazuskiJE, SawyerRG, NathensAB, et al.The Surgical Infection Society guidelines on antimicrobial therapy for intra-abdominal infections: Evidence for the recommendations. Surg Infect (Larchmt), 2002; 3:175–233.
4.
SolomkinJS, MazuskiJE, BradleyJS, et al.Diagnosis and management of complicated intra-abdominal infection in adults and children: Guidelines by the Surgical Infection Society and the Infectious Diseases Society of America. Surg Infect (Larchmt), 2010; 11:79–109.
5.
SolomkinJS, MazuskiJE, BaronEJ, et al.Guidelines for the selection of anti-infective agents for complicated intra-abdominal infections. Clin Infect Dis, 2003; 37:997–1005.
6.
DellingerRP, LevyMM, RhodesA, et al.Surviving Sepsis Campaign: International guidelines for management of severe sepsis and septic shock: 2012. Crit Care Med, 2013; 41:580–637.
7.
GuyattGH, OxmanAD, KunzR, et al.GRADE: What is “quality of evidence” and why is it important to clinicians?. BMJ, 2008; 336:995–998.
8.
GuyattGH, OxmanAD, KunzR, et al.Going from evidence to recommendations. BMJ, 2008; 336:1049–1051.
9.
AtkinsD, BestD, BrissPA, et al.Grading quality of evidence and strength of recommendations. BMJ, 2004; 328:1490.
10.
BeroL, RennieD. The Cochrane Collaboration: Preparing, maintaining, and disseminating systematic reviews of the effects of health care. JAMA, 1995; 274:1935–1938.
11.
JadadAR, MooreRA, CarrollD, et al.Assessing the quality of reports of randomized clinical trials: Is blinding necessary?. Control Clin Trials, 1996; 17:1–12.
12.
SolomkinJS, HemsellDL, SweetR, et al.Evaluation of new anti-infective drugs for the treatment of intraabdominal infections. Infectious Diseases Society of America and the Food and Drug Administration. Clin Infect Dis, 1992; 15(Suppl 1):S33–S42.
13.
BlotS, De WaeleJJ. Critical issues in the clinical management of complicated intra-abdominal infections. Drugs, 2005; 65:1611–1620.
14.
CalandraT, CohenJ, International Sepsis Forum Definition of Infection in the ICU Consensus Conference. The international sepsis forum consensus conference on definitions of infection in the intensive care unit. Crit Care Med, 2005; 33:1538–1548.
15.
ChromikAM, MeiserA, HöllingJ, et al.Identification of patients at risk for development of tertiary peritonitis on a surgical intensive care unit. J Gastrointest Surg, 2009; 13:1358–1367.
16.
MishraSP, TiwarySK, MishraM, GuptaSK. An introduction of tertiary peritonitis. J Emerg Trauma Shock, 2014; 7:121–123.
17.
SeguinP, LaviolleB, ChanavazC, et al.Factors associated with multidrug-resistant bacteria in secondary peritonitis: Impact on antibiotic therapy. Clin Microbiol Infect, 2006; 12:980–985.
18.
AugustinP, KermarrecN, Muller-SerieysC, et al.Risk factors for multidrug resistant bacteria and optimization of empirical antibiotic therapy in postoperative peritonitis. Crit Care, 2010; 14:R20.
19.
SeguinP, FédunY, LaviolleB, et al.Risk factors for multidrug-resistant bacteria in patients with post-operative peritonitis requiring intensive care. J Antimicrob Chemother, 2010; 65:342–346.
20.
BrookI. Bacterial studies of peritoneal cavity and postoperative surgical wound drainage following perforated appendix in children. Ann Surg, 1980; 192:208–212.
21.
BrookI, FrazierEH. Aerobic and anaerobic microbiology in intra-abdominal infections associated with diverticulitis. J Med Microbiol, 2000; 49:827–830.
22.
DupontH, CarbonC, CarletJ. Monotherapy with a broad-spectrum beta-lactam is as effective as its combination with an aminoglycoside in treatment of severe generalized peritonitis: A multicenter randomized controlled trial. Antimicrob Agents Chemother, 2000; 44:2028–2033.
23.
RoehrbornA, ThomasL, PotreckO, et al.The microbiology of postoperative peritonitis. Clin Infect Dis, 2001; 33:1513–1519.
24.
MontraversP, LepapeA, DubreuilL, et al.Clinical and microbiological profiles of community-acquired and nosocomial intra-abdominal infections: Results of the French prospective, observational EBIIA study. J Antimicrob Chemother, 2009; 63:785–794.
25.
LeeYL, ChenYS, TohHS, et al.Antimicrobial susceptibility of pathogens isolated from patients with complicated intra-abdominal infections at five medical centers in Taiwan that continuously participated in the Study for Monitoring Antimicrobial Resistance Trends (SMART) from 2006 to 2010. Int J Antimicrob Agents, 2012; 40(Suppl):S29–S36.
26.
SartelliM, CatenaF, AnsaloniL, et al.Complicated intra-abdominal infections in Europe: A comprehensive review of the CIAO study. World J Emerg Surg, 2012; 7:36.
27.
van RulerO, KiewietJJ, van KetelRJ, et al.Initial microbial spectrum in severe secondary peritonitis and relevance for treatment. Eur J Clin Microbiol Infect Dis, 2012; 31:671–682.
28.
HawserS, HobanDJ, BadalRE, et al.Epidemiology and antimicrobial susceptibility of Gram-negative aerobic bacteria causing intra-abdominal infections during 2010–2011. J Chemother, 2015; 27:67–73.
29.
HsuehPR. Study for monitoring antimicrobial resistance trends (SMART) in the Asia-Pacific region, 2002–2010. Int J Antimicrob Agents, 2012; 40(Suppl):S1–S3.
30.
LobSH, BadalRE, BouchillonSK, et al.Epidemiology and susceptibility of Gram-negative appendicitis pathogens: SMART 2008–2010. Surg Infect, 2013; 14:203–208.
31.
YangQ, ZhangH, WangY, et al.A 10 year surveillance for antimicrobial susceptibility of Escherichia coli and Klebsiella pneumoniae in community- and hospital-associated intra-abdominal infections in China. J Med Microbiol, 2013; 62:1343–1349.
32.
NathensAB, RotsteinOD, MarshallJC. Tertiary peritonitis: Clinical features of a complex nosocomial infection. World J Surg, 1998; 22:158–163.
MazuskiJE. Clinical challenges and unmet needs in the management of complicated intra-abdominal infections. Surg Infect (Larchmt), 2005; 6(Suppl 2):S49–S69.
36.
DellingerEP, WertzMJ, MeakinsJL, et al.Surgical infection stratification system for intra-abdominal infection. Arch Surg, 1985; 120:21–29.
37.
BillingA, FröhlichD, MialkowskyjO, et al.Treatment of peritonitis with staged lavage: Prognostic criteria and course of treatment. (Ger) Langenbecks Arch Chir, 1992; 377:305–313.
38.
ChristouNV, BariePS, DellingerEP, et al.Surgical Infection Society intra-abdominal infection study. Prospective evaluation of management techniques and outcome. Arch Surg, 1993; 128:193–198.
39.
HopkinsJA, LeeJC, WilsonSE. Susceptibility of intra-abdominal isolates at operation: A predictor of postoperative infection. Am Surg, 1993; 59:791–796.
40.
BohnenJM, MustardRA, SchoutenBD. Steroids, APACHE II score, and the outcome of abdominal infection. Arch Surg, 1994:129; 33–37.
41.
SchoeffelU, JacobsE, RufG, et al.Intraperitoneal micro-organisms and the severity of peritonitis. Eur J Surg, 1995; 161:501–508.
42.
ChristouNV, TurgeonP, WassefR, et al.Management of intra-abdominal infections. The case for intraoperative cultures and comprehensive broad-spectrum antibiotic coverage. Arch Surg, 1996; 131:1193–1201.
43.
MontraversP, GauzitR, MullerC, et al.Emergence of antibiotic resistant bacteria in cases of peritonitis after intraabdominal surgery affects the efficacy of empirical antimicrobial therapy. Clin Infect Dis, 1996; 23:486–494.
44.
PacelliF, DogliettoGB, AlfieriS, et al.Prognosis in intra-abdominal infections. Multivariate analysis on 604 patients. Arch Surg, 1996; 131:641–645.
45.
BariePS, VogelSB, DellingerEP, et al.A randomized, double-blind clinical trial comparing cefepime plus metronidazole with imipenem-cilastatin in the treatment of complicated intra-abdominal infections. Arch Surg, 1997; 132:1294–1302.
46.
BosschaK, ReijndersK, HulstaertPF, et al.Prognostic scoring systems to predict outcome in peritonitis and intra-abdominal sepsis. Br J Surg, 1997; 84:1532–1534.
47.
OhmannC, YangQ, HauT, et al: Prognostic modelling in peritonitis. Eur J Surg, 1997; 163:53–60.
48.
WachaH, HauT, DittmerR, OhmannC. Risk factors associated with intraabdominal infections: A prospective multicenter study. Langenbecks Arch Surg, 1999; 384:24–32.
49.
SottoA, LefrantJY, Fabbro-PerayP, et al.Evaluation of antimicrobial therapy management of 120 consecutive patients with secondary peritonitis. J Antimicrob Chemother, 2002; 50:569–576.
50.
HolzheimerRG, GathofB. Re-operation for complicated secondary peritonitis—how to identify patients at risk for persistent sepsis. Eur J Med Res, 2003; 8:125–134.
51.
MulierS, PenninckxF, VerwaestC, et al.Factors affecting mortality in generalized postoperative peritonitis: Multivariate analysis in 96 patients. World J Surg, 2003; 27:379–384.
52.
HutchinsRR, GunningMP, LucasDL, et al.Relaparotomy for suspected intraperitoneal sepsis after abdominal surgery. World J Surg, 2004; 28:137–141.
53.
KrobotK, YinD, ZhangQ, et al.Effect of inappropriate initial empiric antibiotic therapy on outcome of patients with community-acquired intra-abdominal infections requiring surgery. Eur J Clin Microbiol Infect Dis, 2004; 23:682–687.
54.
SturkenboomMCJM, GoettschWG, PicelliG, et al.Inappropriate initial treatment of secondary intra-abdominal infections leads to increased risk of clinical failure and costs. Br J Clin Pharmacol, 2005; 60:438–443.
55.
LammeB, MahlerCW, van RulerO, et al.Clinical predictors of ongoing infection in secondary peritonitis: Systematic review. World J Surg, 2006; 30:2170–2181.
56.
MontraversP, DupontH, GauzitR, et al.Candida as a risk factor for mortality in peritonitis. Crit Care Med, 2006; 34:646–652.
57.
van RulerO, LammeB, GoumaDJ, et al.Variables associated with positive findings at relaparotomy in patients with secondary peritonitis. Crit Care Med, 2007; 35:468–476.
58.
GauzitR, PéanY, BarthX, et al.Epidemiology, management, and prognosis of secondary non-postoperative peritonitis: A French prospective observational multicenter study. Surg Infect (Larchmt), 2009; 10:119–127.
59.
InuiT, HaridasM, ClaridgeJA, MalangoniMA. Mortality for intra-abdominal infection is associated with intrinsic risk factors rather than the source of infection. Surgery, 2009; 146:654–661.
60.
RichéFC, DrayX, LaisnéMJ, et al.Factors associated with septic shock and mortality in generalized peritonitis: Comparison between community-acquired and postoperative peritonitis. Crit Care, 2009; 13:R99.
61.
SchneiderCP, SeybothC, VilsmaierM, et al.Prognostic factors in critically ill patients suffering from secondary peritonitis: A retrospective, observational, survival time analysis. World J Surg, 2009; 33:34–43.
62.
SwensonBR, MetzgerR, HedrickTL, et al.Choosing antibiotics for intra-abdominal infections: What do we mean by “high risk”?. Surg Infect (Larchmt), 2009; 10:29–39.
63.
KimJJ, LiangMK, SubramanianA, et al.Predictors of relaparotomy after nontrauma emergency general surgery with initial fascial closure. Am J Surg, 2011; 202:549–552.
64.
JeanSS, KoWC, XieY, et al.Clinical characteristics of patients with community-acquired complicated intra-abdominal infections: A prospective, multicentre, observational study. Int J Antimicrob Agents, 2014; 44:222–228.
65.
PupelisG, DrozdovaN, MukansM, MalbrainML. Serum procalcitonin is a sensitive marker for septic shock and mortality in secondary peritonitis. Anaesthesiol Intensive Ther, 2014; 46:262–273.
66.
BaeJM. Clinical characteristics of ceftriaxone plus metronidazole in complicated intra-abdominal infection. Ann Surg Treat Res, 2015; 89:43–47.
67.
ChongYP, BaeIG, LeeSR, et al.Clinical and economic consequences of failure of initial antibiotic therapy for patients with community-onset complicated intra-abdominal infections. PLoS One, 2015; 10:e119956.
68.
DupontH, GuilbartM, NtoubaA, et al.Can yeast isolation be predicted in complicated secondary non-postoperative intra-abdominal infections?. Crit Care, 2015; 19:60.
69.
NeriA, MarrelliD, ScheiterleM, et al.Re-evaluation of Mannheim prognostic index in perforative peritonitis: Prognostic role of advanced age. A prospective cohort study. Int J Surg, 2015; 13:54–59.
70.
Suarez-de-la-RicaA, MasedaE, AnilloV, et al.Biomarkers (procalcitonin, C reactive protein, and lactate) as predictors of mortality in surgical patients with complicated intra-abdominal infection. Surg Infect (Larchmt), 2015; 16:346–351.
71.
TellorB, SkrupkyLP, SymonsW, et al.Inadequate source control and inappropriate antibiotics are key determinants of mortality in patients with intra-abdominal sepsis and associated bacteremia. Surg Infect (Larchmt), 2015; 16:785–793.
72.
TridenteA, ClarkeGM, WaldenA, et al.Association between trends in clinical variables and outcome in intensive care patients with faecal peritonitis: Analysis of the GenOSept cohort. Crit Care, 2015; 19:210.
73.
WuQ, RenJ, WangG, et al.The incidence, clinical outcomes, and risk factors of thrombocytopenia in intra-abdominal infection patients: A retrospective cohort study. PLoS One, 2016; 11:e0147482.
74.
VincentJL, MorenoR, TakalaJ, et al.Working group on sepsis-related problems of the European Society of Intensive Care Medicine. The SOFA (sepsis-related organ failure assessment) score to describe organ dysfunction/failure. Intensive Care Med, 1996; 22:707–710.
75.
BlomqvistPG, AnderssonRE, GranathF, et al.Mortality after appendectomy in Sweden, 1987–1996. Ann Surg, 2001; 233:455–460.
76.
DumontR, CinottiR, LejusC, et al.The microbiology of community-acquired peritonitis in children. Pediatr Infect Dis J, 2011; 30:131–135.
77.
SawyerRG, RosenlofLK, AdamsRB, et al.Peritonitis into the 1990s: Changing pathogens and changing strategies in the critically ill. Am Surg, 1992; 58:82–87.
78.
KopernaT, SchulzF. Prognosis and treatment of peritonitis. Do we need new scoring systems?. Arch Surg, 1996; 131:180–186.
79.
PanhoferP, IzayB, RiedlM, et al.Age, microbiology and prognostic scores help to differentiate between secondary and tertiary peritonitis. Langenbecks Arch Surg, 2009; 394:265–271.
80.
SingerM, DeutschmanCS, SeymourCW, et al.The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA, 2016; 315:801–810.
81.
KopernaT, SchulzF. Relaparotomy in peritonitis: Prognosis and treatment of patients with persisting intraabdominal infection. World J Surg, 2000; 24:32–37.
82.
SawyerRG, ClaridgeJA, NathensAB, et al.Trial of short-course antimicrobial therapy for intraabdominal infection. N Engl J Med, 2015; 372:1996–2005.
83.
BillingA, FröhlichD, SchildbergFW. Prediction of outcome using the Mannheim peritonitis index in 2003 patients. Peritonitis Study Group. Br J Surg, 1994; 81:209–213.
84.
GrunauG, HeemkenR, HauT. Predictors of outcome in patients with postoperative intra-abdominal infection. Eur J Surg, 1996; 162:619–625.
85.
RotsteinOD, PruettTL, SimmonsRL. Microbiologic features and treatment of persistent peritonitis in patients in the intensive care unit. Can J Surg, 1986; 29:247–250.
86.
Stiges-SerraA, LópezMJ, GirventM, et al.Postoperative enterococcal infection after treatment of complicated intra-abdominal sepsis. Br J Surg, 2002; 89:361–367.
87.
HasperD, SchefoldJC, BaumgartDC. Management of severe abdominal infections. Recent Pat Antiinfect Drug Discov, 2009; 4:57–65.
88.
CercenadoE, TorrobaL, CantónR, et al.Multicenter study evaluating the role of enterococci in secondary bacterial peritonitis. J Clin Microbiol, 2010; 48:456–459.
89.
DupontH, FriggeriA, TouzeauJ, et al.Enterococci increase the morbidity and mortality associated with severe intra-abdominal infections in elderly patients hospitalized in the intensive care unit. J Antimicrob Chemother, 2011; 66:2379–2385.
90.
FriedrichAK, CahanM. Intraabdominal infections in the intensive care unit. J Intensive Care Med, 2014; 29:247–254.
91.
PeñaC, PujolM, ArdanuyC, et al.Epidemiology and successful control of a large outbreak due to Klebsiella pneumoniae producing extended-spectrum β-lactamases. Antimicrob Agents Chemother, 1998; 42:53–58.
92.
BlotS, DepuydtP, VogelaersD, et al.Colonization status and appropriate antibiotic therapy for nosocomial bacteremia caused by antibiotic-resistant gram-negative bacteria in an intensive care unit. Infect Control Hosp Epidemiol, 2005; 26:575–579.
93.
ZirakzadehA, PatelR. Vancomycin-resistant enterococci: Colonization, infection, detection, and treatment. Mayo Clin Proc, 2006; 81:529–536.
94.
KlevensRM, MorrisonMA, NadleJ, et al.Invasive methicillin-resistant Staphylococcus aureus infections in the United States. JAMA, 2007; 298:1763–1771.
95.
ReddyBS, GattM, SowdiR, et al.Gastric colonization predisposes to septic morbidity in surgical patients: A prospective study. Nutrition, 2008; 24:632–637.
96.
TacconelliE, CataldoMA. Vancomycin-resistant enterococci (VRE): Transmission and control. Int J Antimicrob Agents, 2008; 31:99–106.
97.
HarinsteinL, SchaferJ, D'AmicoF. Risk factors associated with the conversion of meticillin-resistant Staphylococcus aureus colonisation to healthcare-associated infection. J Hosp Infect, 2011; 79:194–197.
98.
SchweickertB, GeffersC, FarragherT, et al.The MRSA-import in ICUs is an important predictor for the occurrence of nosocomial MRSA cases. Clin Microbiol Infect, 2011; 17:901–906.
99.
HanJH, NachamkinI, ZaoutisTE, et al.Risk factors for gastrointestinal tract colonization with extended-spectrum β-lactamase (ESBL)-producing Escherichia coli and Klebsiella species in hospitalized patients. Infect Cont Hosp Epidemiol, 2012; 33:1242–1245.
100.
TongSYC, ChenLF, FowlerVGJr. Colonization, pathogenicity, host susceptibility, and therapeutics for Staphylococcus aureus: What is the clinical relevance?. Semin Immunopathol, 2012; 34:185–200.
101.
Di CarloP, GulottaG, CasuccioA, et al.KPC - 3 Klebsiella pneumoniae ST258 clone infection in postoperative abdominal surgery patients in an intensive care setting: Analysis of a case series of 30 patients. BMC Anesthesiol, 2013; 13:13.
ZiakasPD, ThapaR, RiceLB, MylonakisE. Trends and significance of VRE colonization in the ICU: A meta-analysis of published studies. PLoS One, 2013; 8:e75658.
104.
GiannellaM, TrecarichiEM, De RosaFG, et al.Risk factors for carbapenem-resistant Klebsiella pneumoniae bloodstream infection among rectal carriers: A prospective observational multicentre study. Clin Microbiol Infect, 2014; 20:1357–1562.
105.
LübbertC, Becker-RuxD, RodloffAC, et al.Colonization of liver transplant recipients with KPC-producing Klebsiella pneumoniae is associated with high infection rates and excess mortality: A case–control analysis. Infection, 2014; 42:309–316.
106.
O'Driscoll, CrankCW. Vancomycin-resistant enterococcal infections: Epidemiology, clinical manifestations, and optimal management. Infect Drug Resist, 2015; 8:217–230.
107.
BayerAS, BlumenkrantzMJ, MontgomerieJZ, et al.Candida peritonitis. Report of 22 cases and review of the English literature. Am J Med, 1976; 61:832–840.
108.
GreweM, TsiotosGG, Luque de-LeonE, SarrMG. Fungal infection in acute necrotizing pancreatitis. J Am Coll Surg, 1999; 188:408–414.
109.
IsenmannR, SchwarzM, RauB, et al.Characteristics of infection with Candida species in patients with necrotizing pancreatitis. World J Surg, 2002; 26:372–376.
110.
DupontH, BourichonA, Paugam-BurtzC, et al.Can yeast isolation in peritoneal fluid be predicted in intensive care unit patients with peritonitis?. Crit Care Med, 2003; 31:752–757.
111.
HarbarthS, UckayI. Are there patients with peritonitis who require empiric therapy for enterococcus?. Eur J Clin Microbiol Infect Dis, 2004; 23:73–77.
112.
CisnerosJM, Rodríguez-BañoJ, Fernández-CuencaF, et al.Risk-factors for the acquisition of imipenem-resistant Acinetobacter baumannii in Spain: A nationwide study. Clin Microbiol Infect, 2005; 11:874–879.
113.
GeorgesB, ConilJM, DubouixA, et al.Risk of emergence of Pseudomonas aeruginosa resistance to β-lactam antibiotics in intensive care units. Crit Care Med, 2006; 34:1636–1641.
114.
PeñaC, GudiolC, TubauF, et al.Risk-factors for acquisition of extended-spectrum β-lactamase-producing Escherichia coli among hospitalised patients. Clin Microbiol Infect, 2006; 12:279–284.
115.
LindenPK. Optimizing therapy for vancomycin-resistant enterococci (VRE). Semin Respir Crit Care Med, 2007; 28:632–645.
116.
Ben-AmiR, Rodríguez-BañoJ, ArslanH, et al.A multinational survey of risk factors for infection with extended-spectrum β-lactamase-producing enterobacteriaceae in nonhospitalized patients. Clin Infect Dis, 2009; 49:682–690.
117.
Fernández-CuencaF, Gómez-SánchezM, Rodríguez-BañoJ, et al.Epidemiological and clinical features associated with colonisation/infection by Acinetobacter baumannii with phenotypic heterogeneous resistance to carbapenems. Int J Antimicrob Agents, 2012; 40:235–238.
118.
SamuelssonA, IsakssonB, ChabokA, et al.Changes in the aerobic faecal flora of patients treated with antibiotics for acute intra-abdominal infection. Scand J Infect Dis, 2012; 44:820–827.
119.
SeguinP, BrianchonC, LauneyY, et al.Are enterococci playing a role in postoperative peritonitis in critically ill patients?. Eur J Clin Microbiol Infect Dis, 2012; 31:1479–1485.
120.
SiedelmanL, KlineS, DuvalS. Risk factors for community- and health facility-acquired extended-spectrum β-lactamase-producing bacterial infections in patients at the University of Minnesota Medical Center, Fairview. Am J Infect Cont, 2012; 40:849–853.
121.
LiewYX, TanTT, LeeW, et al.Risk factors for extreme-drug resistant Pseudomonas aeruginosa infections in patients with hematologic malignancies. Am J Infect Cont, 2013; 41:140–144.
122.
CohenMJ, BlockCS, MosesAE, Nir-PazR. Exposure to ertapenem is possibly associated with Pseudomonas aeruginosa antibiotic resistance. Clin Microbiol Infect, 2014; 20:O188–O196.
123.
TumbarelloT, TrecarichiEM, TumiettoF, et al.Predictive models for identification of hospitalized patients harboring KPC-producing Klebsiella pneumoniae. Antimicrob Agents Chemother, 2014; 58:3514–3520.
124.
ChalmersJD, RotherC, SalihW, EwigS. Healthcare-associated pneumonia does not accurately identify potentially resistant pathogens: A systematic review and meta-analysis. Clin Infect Dis, 2014; 58:330–339.
125.
American Thoracic Society, Infectious Diseases Society of America. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med, 2005; 171:388–416.
126.
BohnenJM, MarshallJC, FryDE, et al.Clinical and scientific importance of source control in abdominal infections: Summary of a symposium. Can J Surg, 1999; 42:122–126.
127.
MarshallJC, InnesM. Intensive care unit management of intra-abdominal infection. Crit Care Med, 2003; 31:2228–2237.
128.
MarshallJC, MaierRV, JimenezM, DellingerEP. Source control in the management of severe sepsis and septic shock: An evidence-based review. Crit Care Med, 2004; 32[,Suppl]:S513–S526.
129.
PieracciFM, BariePS. Intra-abdominal infections. Curr Opin Crit Care, 2007; 13:440–449.
130.
WeigeltJA. Empiric treatment options in the management of complicated intra-abdominal infections. Cleve Clin J Med, 2007; 74(Suppl 4);S29–S37.
131.
AndewegCS, MulderIM, Felt-BersmaRJ, et al.Guidelines of diagnostics and treatment of acute left-sided colonic diverticulitis. Dig Surg, 2013; 30:278–292.
132.
FeingoldD, SteeleSR, LeeS, et al.Practice parameters for the treatment of sigmoid diverticulitis. Dis Colon Rectum, 2014; 57:284–294.
133.
NadlerEP, ReblockKK, VaughanKG, et al.Predictors of outcome for children with perforated appendicitis initially treated with non-operative management. Surg Infect (Larchmt), 2004; 5:349–356.
134.
AnderssonRE, PetzoldMG. Nonsurgical treatment of appendiceal abscess or phlegmon: A systematic review and meta-analysis. Ann Surg, 2007; 246:741–748.
135.
SimillisC, SymeonidesP, ShorthouseAJ, TekkisPP. A meta-analysis comparing conservative treatment versus acute appendectomy for complicated appendicitis (abscess or phlegmon). Surgery, 2010; 147:818–829.
136.
CroftsTJ, ParkKG, SteeleRJ, et al.A randomized trial of nonoperative treatment for perforated peptic ulcer. N Engl J Med, 1989; 320:970–973.
137.
MarshallC, RamaswamyP, BerginFG, et al.Evaluation of a protocol for the non-operative management of perforated peptic ulcer. Br J Surg, 1999; 86:131–134.
138.
CaoF, LiJ, LiA, et al.Nonoperative management for perforated peptic ulcer: Who can benefit?. Asian J Surg, 2014; 37:148–153.
139.
JeffreyRB, FederleMP, TolentinoCS. Periappendiceal inflammatory masses: CT-directed management and clinical outcome in 70 patients. Radiology, 1988; 167:13–16.
140.
BrandtD, GervazP, DurmishiY, et al.Percutaneous CT scan-guided drainage vs. antibiotherapy alone for Hinchey II diverticulitis: A case-control study. Dis Colon Rectum, 2006; 49:1533–1538.
141.
SiewertB, TyeG, KruskalJ, et al.Impact of CT-guided drainage in the treatment of diverticular abscesses: Size matters. AJR Am J Roentgenol, 2006; 186:680–686.
142.
DharmarajanS, HuntSR, BirnbaumEH, et al.The efficacy of nonoperative management of acute complicated diverticulitis. Dis Colon Rectum, 2011; 54:663–671.
143.
BakkerOJ, van SantvoortHC, BesselinkMG, et al.Prevention, detection, and management of infected necrosis in severe acute pancreatitis. Curr Gastroenterol Rep, 2009; 11:104–110.
144.
MouliVP, SreenivasV, GargPK. Efficacy of conservative treatment, without necrosectomy, for infected pancreatic necrosis: A systematic review and meta-analysis. Gastroenterology, 2013; 144:333–340.
145.
MentulaP, LeppäniemiA. Position paper: Timely interventions in severe acute pancreatitis are crucial for survival. World J Emerg Surg, 2014; 9:15.
146.
De WaeleJJ. Early source control in sepsis. Langenbecks Arch Surg, 2010; 395:489–494.
147.
BloosF, Thomas-RüddelD, RüddelH, et al.Impact of compliance with infection management guidelines on outcome in patients with severe sepsis: A prospective observational multi-center study. Crit Care, 2014; 18:R42.
148.
HeckerA, SchneckE, RöhrigR, et al.The impact of early surgical intervention in free intestinal perforation: A time-to-intervention pilot study. World J Emerg Surg, 2015; 10:54.
149.
van GoorH. Interventional management of abdominal sepsis: When and how. Langenbecks Arch Surg, 2002; 387:191–200.
150.
BetschA, WiskirchenJ, TrübenbachJ, et al.CT-guided percutaneous drainage of intra-abdominal abscesses: APACHE III score stratification of 1-year results. Eur Radiol, 2002; 12:2883–2889.
151.
CinatME, WilsonSE, DinAM. Determinants for successful percutaneous image-guided drainage of intra-abdominal abscess. Arch Surg, 2002; 137:845–849.
152.
AkinciD, AkhanO, OzmenMN, et al.Percutaneous drainage of 300 intraperitoneal abscesses with long-term follow-up. Cardiovasc Intervent Radiol, 2005; 28:744–750.
153.
TheisenJ, BartelsH, WeissW, et al.Current concepts of percutaneous abscess drainage in postoperative retention. J Gastrointest Surg, 2005; 9:280–283.
ToorenvlietBR, SwankH, SchoonesJW, et al.Laparoscopic peritoneal lavage for perforated colonic diverticulitis: A systematic review. Colorectal Dis, 2010; 12:862–867.
156.
RossiGL, MentzR, BertoneS, et al.Laparoscopic peritoneal lavage for Hinchey III diverticulitis: Is it as effective as it is applicable?. Dis Colon Rectum, 2014; 57:1384–1390.
157.
CirocchiR, TrastulliS, VettorettoN, et al.Laparoscopic peritoneal lavage: A definitive treatment for diverticular peritonitis or a “bridge” to elective laparoscopic sigmoidectomy? A systematic review. Medicine (Baltimore), 2015; 94:e334.
158.
SchultzJK, YaqubS, WallonC, et al.Laparoscopic lavage vs primary resection for acute perforated diverticulitis. The SCANDIV randomized clinical trial. JAMA, 2015; 314:1364–1375.
159.
VennixS, MustersGD, MulderIM, et al.Laparoscopic peritoneal lavage or sigmoidectomy for perforated diverticulitis with purulent peritonitis: A multicentre, parallel-group, randomised, open-label trial. Lancet, 2015:386:1269–1277.
160.
KiewietJJ, van RulerO, BoermeesterMA, ReitsmaJB. A decision rule to aid selection of patients with abdominal sepsis requiring a relaparotomy. BMC Surg, 2013; 13:28.
161.
OrdoñezCA, PuyanaJC. Management of peritonitis in the critically ill patient. Surg Clin North Am, 2006; 86:1323–1349.
162.
WeberDG, BendinelliC, BaloghZJ. Damage control surgery for abdominal emergencies. Br J Surg, 2014; 101:e109–e118.
163.
DiazJJJr, CullinaneDC, DuttonWD, et al.The management of the open abdomen in trauma and emergency general surgery: Part 1—Damage control. J Trauma, 2010; 68:1425–1438.
164.
WaibelBH, RotondoMF. Damage control for intra-abdominal sepsis. Surg Clin North Am, 2012; 92:243–257.
165.
BaloghZJ, LeppäniemiA. Patient populations at risk for intra-abdominal hypertension and abdominal compartment syndrome. Am Surg, 2011; 77(Suppl 1):S12–S16.
166.
ScheinM. Surgical management of intra-abdominal infection: Is there any evidence?. Langenbecks Arch Surg, 2002; 387:1–7.
167.
LeeJC, PeitzmanAB. Damage-control laparotomy. Curr Opin Crit Care, 2006; 12:346–350.
168.
StawickiSP, BrooksA, BilskiT, et al.The concept of damage control: Extending the paradigm to emergency general surgery. Injury, 2008; 39:93–101.
169.
KhanA, HseeL, MathurS, CivilI. Damage-control laparotomy in nontrauma patients: Review of indications and outcomes. J Trauma Acute Care Surg, 2013; 75:365–368.
170.
van RulerO, MahlerCW, BoerKR, et al.Comparison of on-demand vs planned relaparotomy strategy in patients with severe peritonitis: A randomized trial. JAMA, 2007; 298:865–872.
171.
OpmeerBC, BoerKR, van RulerO, et al.Costs of relaparotomy on-demand versus planned relaparotomy in patients with severe peritonitis: An economic evaluation within a randomized controlled trial. Crit Care, 2010; 14:R97.
172.
SeilerCA, BrüggerL, ForssmannU, et al.Conservative surgical treatment of diffuse peritonitis. Surgery, 2000; 127:178–184.
173.
LammeB, BoermeesterMA, BeltEJ, et al.Mortality and morbidity of planned relaparotomy versus relaparotomy on demand for secondary peritonitis. Br J Surg, 2004; 91:1046–1054.
174.
RobledoFA, Luque-de-LeónE, SuárezR, et al.Open versus closed management of the abdomen in the surgical treatment of severe secondary peritonitis: A randomized clinical trial. Surg Infect, 2007; 8:63–72.
175.
ZhangWB, LiN, WangPF, et al.Infections following damage control laparotomy with abdominal packing. Scand J Infect Dis, 2008; 40:867–876.
176.
MoussavianMR, RichterS, KollmarO, et al.Staged lavage versus single high-volume lavage in the treatment of feculent/purulent peritonitis: A matched pair analysis. Langenbecks Arch Surg, 2009; 394:215–220.
177.
MandellK, ArbabiS. Re-laparotomy for severe intra-abdominal infections. Surg Infect (Larchmt), 2010; 11:307–310.
178.
PlatellC, PapadimitriouJM, HallJC. The influence of lavage on peritonitis. J Am Coll Surg, 2000; 191:672–680.
179.
MooreCB, SmithRS, HerbertsonR, ToevsC. Does use of intraoperative irrigation with open or laparoscopic appendectomy reduce post-operative intra-abdominal abscess?. Am Surg, 2011; 77:78–80.
180.
AkkoyunI, TunaAT. Advantages of abandoning abdominal cavity irrigation and drainage in operations performed on children with perforated appendicitis. J Pediatr Surg, 2012; 47:1886–1890.
181.
St. Peter SD, Adibe OO, Iqbal CW, et al. Irrigation versus suction alone during laparoscopic appendectomy for perforated appendicitis: A prospective randomized trial. Ann Surg, 2012; 256:581–585.
182.
HartwichJE, CarterRF, WolfeL, et al.The effects of irrigation on outcomes in cases of perforated appendicitis in children. J Surg Res, 2013; 180:222–225.
183.
LeiboffAR, SoroffHS. The treatment of generalized peritonitis by closed postoperative peritoneal lavage. A critical review of the literature. Arch Surg, 1987; 122:1005–1010.
184.
SudingPN, OrricoRP, JohnsonSB, WilsonSE. Concordance of interrater assessments of surgical methods to achieve source control of intra-abdominal infections. Am J Surg, 2008; 196:70–73.
185.
SolomkinJS, RistagnoRL, DasAF, et al.Source control review in clinical trials of anti-infective agents in complicated intra-abdominal infections. Clin Infect Dis, 2013; 56:1765–1773.
186.
DaviesHO, AlkhamesiNA, DawsonPM. Peritoneal fluid culture in appendicitis: Review in changing times. Int J Surg, 2010; 8:426–429.
187.
MosdellDM, MorrisDM, VolturaA, et al.Antibiotic treatment for surgical peritonitis. Ann Surg, 1991; 214:543–549.
188.
KokoskaER, SilenML, TracyTFJr, et al.The impact of intraoperative culture on treatment and outcome in children with perforated appendicitis. J Pediatr Surg, 1999; 34:749–753.
189.
ÇelikA, ErgünO, OzcanC, et al.Is it justified to obtain routine peritoneal cultures during appendectomy in children?. Pediatr Surg Int, 2003; 19:632–634.
190.
GladmanMA, KnowlesCH, GladmanLJ, PayneJG. Intra-operative culture in appendicitis: Traditional practice challenged. Ann R Coll Surg Engl, 2004; 86:196–201.
191.
KhanMN, VidyaR, LeeRE. Are routine peritoneal fluid cultures during appendicectomy justified?. Ir J Med Sci, 2007; 176:37–40.
192.
EdelsbergJ, BergerA, SchellS, et al.Economic consequences of failure of initial antibiotic therapy in hospitalized adults with complicated intra-abdominal infections. Surg Infect (Larchmt), 2008; 9:335–347.
193.
KollefMH, ShermanG, WardS, FraserVJ. Inadequate antimicrobial treatment of infections: A risk factor for hospital mortality among critically ill patients. Chest, 1999; 115:462–474.
194.
Garnacho-MonteroJ, Ortiz-LeybaC, Herrera-MeleroI, et al.Mortality and morbidity attributable to inadequate empirical antimicrobial therapy in patients admitted to the ICU with sepsis: A matched cohort study. J Antimicrob Chemother, 2008; 61:436–441.
195.
PaulM, ShaniV, MuchtarE, et al.Systematic review and meta-analysis of the efficacy of appropriate empiric antibiotic therapy for sepsis. Antimicrob Agents Chemother, 2010; 54:4851–4863.
196.
DellitTH, OwensRC, McGowanJEJr., et al.Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America guidelines for developing an institutional program to enhance antimicrobial stewardship. Clin Infect Dis, 2007; 44:159–177.
197.
CottaMO, RobertsJA, TabahA, et al.Antimicrobial stewardship of β-lactams in intensive care units. Expert Rev Anti Infect Ther, 2014; 12:581–595.
198.
Garnacho-MonteroJ, Gutiérrez-PizarrayaA, Escoresca-OrtegaA, et al.De-escalation of empirical therapy is associated with lower mortality in patients with severe sepsis and septic shock. Intensive Care Med, 2014; 40:32–40.
MacGowan AP; BSAC Working Parties on Resistance Surveillance. Clinical implications of antimicrobial resistance for therapy. J Antimicrob Chemother, 2008; 62(Suppl 2):ii105–ii114.
201.
HeseltinePN, YellinAE, ApplemanMD, et al.Perforated and gangrenous appendicitis: An analysis of antibiotic failures. J Infect Dis, 1983; 148:322–329.
202.
BaréM, CastellsX, GarciaA, et al.Importance of appropriateness of empiric antibiotic therapy on clinical outcomes in intra-abdominal infections. Int J Technol Assess Health Care, 2006; 22:242–248.
203.
ChandraA, DharP, DharapS, et al.Cefoperazone-sulbactam for treatment of intra-abdominal infections: Results from a randomized, parallel group study in India. Surg Infect (Larchmt), 2008; 9:367–376.
204.
St. Peter SD, Tsao K, Spilde TL, et al. Single daily dosing ceftriaxone and metronidazole vs standard triple antibiotic regimen for perforated appendicitis in children: A prospective randomized trial. J Pediatr Surg, 2008; 43:981–985.
205.
DalgicN, KaradagCA, BayraktarB, et al.Ertapenem versus standard triple antibiotic therapy for the treatment of perforated appendicitis in pediatric patients: A prospective randomized trial. Eur J Pediatr Surg, 2014; 24:410–418.
206.
PérezV, SaénzD, MadrizJ, et al.A double-blind study of the efficacy and safety of multiple daily doses of amikacin versus one daily dose for children with perforated appendicitis in Costa Rica. Int J Infect Dis, 2011; 15:e569-e575.
207.
BaileyJA, VirgoKS, DiPiroJT, et al.Aminoglycosides for intra-abdominal infection: Equal to the challenge?. Surg Infect (Larchmt), 2002; 3:315–335.
208.
FalagasME, MatthaiouDK, KarveliEA, PeppasG. Meta-analysis: Randomized controlled trials of clindamycin/aminoglycoside vs. β-lactam monotherapy for the treatment of intra-abdominal infections. Aliment Pharmacol Ther, 2007; 25:537–556.
209.
JaureguiLE, AppelbaumPC, FabianTC, et al.A randomized clinical study of cefoperazone and sulbactam versus gentamicin and clindamycin in the treatment of intra-abdominal infections. J Antimicrob Chemother, 1990; 25:423–433.
210.
KooiGH, PitS. Ceftazidime/metronidazole versus netilmicin/metronidazole in the treatment of perforated appendicitis in children. Clin Ther, 1990; 12:54–60.
211.
SolomkinJS, DellingerEP, ChristouNV, BusuttilRW. Results of a multicenter trial comparing imipenem/cilastatin to tobramycin/clindamycin for intra-abdominal infections. Ann Surg, 1990; 212:581–591.
212.
LukeM, IversenJ, SøndergaardJ, et al.Ceftriaxone/metronidazole is more effective than ampicillin/netilmicin/metronidazole in the treatment of bacterial peritonitis. Eur J Surg, 1991; 157:397–401.
213.
YellinAE, HeseltinePN, BerneTV, et al.The role of Pseudomonas species in patients treated with ampicillin and sulbactam for gangrenous and perforated appendicitis. Surg Gynecol Obstet, 1985; 161:303–307.
214.
CatenaF, VallicelliC, AnsaloniL, et al.T.E.A. study: Three-day ertapenem versus three-day ampicillin-sulbactam. BMC Gastroenterol, 2013; 13:76.
215.
ChenCW, MingCC, MaCJ, et al.Prospective, randomized, study of ampicillin-sulbactam versus moxifloxacin monotherapy for the treatment of community-acquired complicated intra-abdominal infections. Surg Infect (Larchmt), 2013; 14:389–396.
216.
BetrosianAP, DouzinasEE. Ampicillin-sulbactam: An update on the use of parenteral and oral forms in bacterial infections. Expert Opin Drug Metab Toxicol, 2009; 5:1099–1112.
217.
YoshiokaK, YoungsDJ, KeighleyMR. A randomized prospective controlled study of ciprofloxacin with metronidazole versus amoxicillin/clavulanic acid with metronidazole in the treatment of intra-abdominal infection. Infection, 1991; 19:25–29.
218.
Rahnama’1MS, WagenvoortJH, van der LindenCJ. Amoxicillin/clavulanate (Augmentin) resistant Escherichia coli in bacterial peritonitis after abdominal surgery—clinical outcome in ICU patients. Neth J Med, 2009; 67:173–176.
219.
KacmazB, SultanN. In vitro susceptibilities of Escherichia coli and Klebsiella spp. to ampicillin-sulbactam and amoxicillin-clavulanic acid. Jpn J Infect Dis, 2007; 60:227–229.
220.
YellinAE, JohnsonJ, HigaredaI, et al.Ertapenem or ticarcillin/clavulanate for the treatment of intra-abdominal infections or acute pelvic infections in pediatric patients. Am J Surg, 2007; 194:367–374.
221.
JonesRN, StilwellMG, RhombergPR, SaderHS. Antipseudomonal activity of piperacillin/tazobactam: More than a decade of experience from the SENTRY Antimicrobial Surveillance Program (1997–2007). Diag Microbiol Infect Dis, 2009; 65:331–334.
222.
HigginsPG, WisplinghoffH, StefanikD, SeifertH. In vitro activities of the β-lactamase inhibitors clavulanic acid, sulbactam, and tazobactam alone or in combination with β-lactams against epidemiologically characterized multidrug-resistant Acinetobacter baumannii strains. Antimicrob Agents Chemother, 2004; 48:1586–1592.
223.
PayneDJ, CrampR, WinstanleyDJ, KnowlesDJ. Comparative activities of clavulanic acid, sulbactam, and tazobactam against clinically important β-lactamases. Antimicrob Agents Chemother, 1994; 38:767–772.
MaltezouHC, NikolaidisP, LebesiiE, et al.Piperacillin/tazobactam versus cefotaxime plus metronidazole for treatment of children with intra-abdominal infections requiring surgery. Eur J Clin Microbiol Infect Dis, 2001; 20:643–646.
226.
SolomkinJS, YellinAE, RotsteinOD, et al.Ertapenem versus piperacillin/tazobactam in the treatment of complicated intraabdominal infections: Results of a double-blind, randomized comparative phase III trial. Ann Surg, 2003; 237:235–245.
227.
ErasmoAA, CrisostomoAC, YanLN, et al.Randomized comparison of piperacillin/tazobactam versus imipenem/cilastatin in the treatment of patients with intra-abdominal infection. Asian J Surg, 2004; 27:227–235.
228.
Dela PenaAS, AspergerW, KöckerlingF, et al.Efficacy and safety of ertapenem versus piperacillin-tazobactam for the treatment of intra-abdominal infections requiring surgical intervention. J Gastroint Surg, 2006; 10:567–574.
229.
MalangoniMA, SongJ, HerringtonJ, et al.Randomized controlled trial of moxifloxacin compared with piperacillin-tazobactam and amoxicillin-clavulanate for the treatment of complicated intra-abdominal infections. Ann Surg, 2006; 244:204–211.
230.
NamiasN, SolomkinJS, JensenEH, et al.Randomized, multicenter, double-blind study of efficacy, safety, and tolerability of intravenous ertapenem versus piperacillin/tazobactam in treatment of complicated intra-abdominal infections in hospitalized adults. Surg Infect (Larchmt), 2007; 8:15–28.
231.
ItaniKM, WilsonSE, AwadSS, et al.Ertapenem versus cefotetan prophylaxis in elective colorectal surgery. N Engl J Med, 2006; 355:2640–2651.
232.
DeierhoiRJ, DawesLG, VickC, et al.Choice of intravenous antibiotic prophylaxis for colorectal surgery does matter. J Am Coll Surg, 2013; 217:763–769.
233.
HendrenS, FritzeD, BanerjeeM, et al.Antibiotic choice is independently associated with risk of surgical site infection after colectomy. A population-based cohort study. Ann Surg, 2013; 257:469–475.
234.
BabinchakT, BadalR, HobanD, et al.Trends in susceptibility of selected gram-negative bacilli isolated from intra-abdominal infections in North America: SMART 2005–2010. Diagn Microbiol Infect Dis, 2013; 76:379–381.
235.
VillegasMV, BlancoMG, Sifuentes-OsornioJ, RossiF. Increasing prevalence of extended-spectrum-beta-lactamase among Gram-negative bacilli in Latin America —2008 update from the Study for Monitoring Antimicrobial Resistance Trends (SMART). Braz J Infect Dis, 2011; 15:34–39.
236.
BoyanovaL, KolarovR, MitovI. Recent evolution of antibiotic resistance in the anaerobes as compared to previous decades. Anaerobe, 2015; 31:4–10.
237.
ClarosM, CitronDM, GoldsteinEJ, et al.Differences in distribution and antimicrobial susceptibility of anaerobes isolated from complicated intra-abdominal infections versus diabetic foot infections. Diag Microbiol Infect Dis, 2013; 76:546–548.
238.
BratzlerDW, DellingerEP, OlsenKM, et al.Clinical practice guidelines for antimicrobial prophylaxis in surgery. Surg Infect (Larchmt), 2013; 14:73–156.
el-SefiTA, el-AwadyHM, ShehataMI, al-HindiMA. Systemic plus local metronidazole and cephazolin in complicated appendicitis: A prospective controlled trial. J R Coll Surg Edinb, 1989; 34:13–16.
241.
ChenCY, ChenYC, PuHN, et al.Bacteriology of acute appendicitis and its implication for the use of prophylactic antibiotics. Surg Infect (Larchmt), 2012; 13:383–390.
242.
SchitoGC, NaberKG, BottoH, et al.The ARESC study: An international survey on the antimicrobial resistance of pathogens involved in uncomplicated urinary tract infections. Int J Antimicrob Agents, 2009; 34:407–413.
243.
HuizingaWK, WarrenBL, BakerLW, et al.Antibiotic monotherapy with meropenem in the surgical management of intra-abdominal infections. J Antimicrob Chemother, 1995; 36(Suppl A):179–189.
244.
KempfP, BauernfeindA, MüllerA, BlumJ. Meropenem monotherapy versus cefotaxime plus metronidazole combination treatment for serious intra-abdominal infections. Infection, 1996; 24:473–479.
245.
Hoogkamp-KorstanjeJA. Ciprofloxacin vs. cefotaxime regimens for the treatment of intra-abdominal infections. Infection, 1995; 23:278–282.
246.
YellinAE, HassettJM, FernandezA, et al.Ertapenem monotherapy versus combination therapy with ceftriaxone plus metronidazole for treatment of complicated intra-abdominal infections in adults. Int J Antimicrob Agents, 2002; 20:165–173.
247.
StarakisI, KarraviasD, AsimakopoulosC, et al.Results of a prospective, randomized, double blind comparison of the efficacy and the safety of sequential ciprofloxacin (intravenous/oral) + metronidazole (intravenous/oral) with ceftriaxone (intravenous) +/metronidazole (intravenous/oral) for the treatment of intra-abdominal infections. Int J Antimicrobial Agents, 2003; 21:49–57.
248.
NavarroNSJr, CamposMI, AlvaradoR, et al.Ertapenem versus ceftriaxone and metronidazole as treatment for complicated intra-abdominal infections. Int J Surg, 2005; 3:25–34.
249.
WachaH, WarrenB, BassarisH, et al.Comparison of sequential intravenous/oral ciprofloxacin plus metronidazole with intravenous ceftriaxone plus metronidazole for treatment of complicated intra-abdominal infections. Surg Infect (Larchmt), 2006; 7:341–354.
250.
SolomkinJ, ZhaoYP, MaEL, et al.Moxifloxacin is non-inferior to combination therapy with ceftriaxone plus metronidazole in patients with community-origin complicated intra-abdominal infections. Int J Antimicrobial Agents, 2009; 34:439–445.
251.
WeissG, ReimnitzP, HampelB, et al.Moxifloxacin for the treatment of patients with complicated intra-abdominal infections (the AIDA Study). J Chemother, 2009; 21:170–180.
252.
TowfighS, PasternakJ, PoirierA. A multicentre, open-label, randomized comparative study of tigecycline versus ceftriaxone sodium plus metronidazole for the treatment of hospitalized subjects with complicated intra-abdominal infections. Clin Microbiol Infect, 2010; 16:1274–1281.
253.
QvistN, WarrenB, Leister-TebbeH, et al.Efficacy of tigecycline versus ceftriaxone plus metronidazole for the treatment of complicated intra-abdominal infections: Results from a randomized, controlled trial. Surg Infect (Larchmt), 2012; 13:102–109.
254.
BadaróR, MolinarF, SeasC, et al.A multicenter comparative study of cefepime versus broad-spectrum antibacterial therapy in moderate and severe bacterial infections. Braz J Infect Dis, 2002; 6:206–218.
255.
GarbinoJ, VilligerP, CaviezelA, et al.A randomized prospective study of cefepime plus metronidazole with imipenem-cilastatin in the treatment of intra-abdominal infections. Infection, 2007; 35:161–166.
HarrisPN, TambyahPA, PatersonDL. β-Lactam and β-lactamase inhibitor combinations in the treatment of extended-spectrum β-lactamase producing Enterobacteriaceae: Time for a reappraisal in the era of few antibiotic options?. Lancet Infect Dis, 2015; 15:475–485.
258.
TammaPD, GirdwoodSCT, GopaulR, et al.The use of cefepime for treating AmpC β-lactamase-producing Enterobacteriaceae. Clin Infect Dis, 2013; 57:781–788.
259.
BlanchetteLM, KutiJL, NicolauDP, NailorMD. Clinical comparison of ertapenem and cefepime for treatment of infections caused by AmpC beta-lactamase-producing Enterobacteriaceae. Scand J Infect Dis, 2014; 46:803–808.
260.
IshiiY, UedaC, KouyamaY, et al.Evaluation of antimicrobial susceptibility for β-lactams against clinical isolates from 51 medical centers in Japan (2008). Diag Microbiol Infect Dis, 2011; 69:443–448.
261.
JonesRN, Guzman-BlancoM, GalesAC, et al.Susceptibility rates in Latin American nations: Report from a regional resistance surveillance program (2011). Braz J Infect Dis, 2013; 17:672–681.
262.
JonesRN, CastanheiraM, HuB, et al.Update of contemporary antimicrobial resistance rates across China: Reference testing results for 12 medical centers (2011). Diagn Microbiol Infect Dis, 2013; 77:258–266.
263.
LucastiC, HershbergerE, MillerM, et al.Multicenter, double-blind, randomized, phase II trial to assess the safety and efficacy of ceftolozane-tazobactam plus metronidazole compared with meropenem in adult patients with complicated intra-abdominal infections. Antimicrob Agents Chemother, 2014; 58:5350–5357.
264.
SolomkinJ, HershbergerE, MillerB, et al.Ceftolozane/tazobactam plus metronidazole for complicated intra-abdominal infections in an era of multidrug resistance: Results from a randomized, double-blind, phase 3 trial (ASPECT-cIAI). Clin Infect Dis, 2015; 60:1462–1471.
265.
MasedaE, AguilarL, GimenezMJ, GilsanzF. Ceftolozane/tazobactam (CXA 201) for the treatment of intra-abdominal infections. Exp Review Anti Infect Ther, 2014; 12:1311–1324.
266.
ZhanelGG, ChungP, AdamH, et al.Ceftolozane/tazobactam: A novel cephalosporin/β- lactamase inhibitor combination with activity against multidrug-resistant gram-negative bacilli. Drugs, 2014; 74:31–51.
LiscioJL, MahoneyMV, HirschEB. Ceftolozane/tazobactam and ceftazidime/avibactam: Two novel β-lactam/β-lactamase inhibitor combination agents for the treatment of resistant Gram-negative bacterial infections. Int J Antimicrob Agents, 2015; 46:266–271.
269.
WalktyA, KarlowskyJA, AdamH, et al.In vitro activity of ceftolozane-tazobactam against Pseudomonas aeruginosa isolates obtained from patients in Canadian hospitals in the CANWARD study, 2007 to 2012. Antimicrob Agents Chemother, 2013; 57:5707–5709.
270.
FarrellDJ, FlammRK, SaderHS, JonesRN. Antimicrobial activity of ceftolozane-tazobactam tested against Enterobacteriaceae and Pseudomonas aeruginosa with various resistance patterns isolated in U.S. hospitals (2011–2012). Antimicrob Agents Chemother, 2013; 57:6305–6310.
271.
FarrellDJ, SaderHS, FlammRK, JonesRN. Ceftolozane/tazobactam activity tested against Gram-negative bacterial isolates from hospitalised patients with pneumonia in US and European medical centres (2012). Int J Antimicrob Agents, 2014; 43:533–539.
272.
SaderHS, FarrellDJ, CastanheiraM, et al.Antimicrobial activity of ceftolozane/tazobactam tested against Pseudomonas aeruginosa and Enterobacteriaceae with various resistance patterns isolated in European hospitals (2011–12). J Antimicrob Chemother, 2014; 69:2713–2722.
273.
SaderHS, FarrellDJ, FlammRK, JonesRN. Ceftolozane/tazobactam activity tested against aerobic Gram-negative organisms isolated from intra-abdominal and urinary tract infections in European and United States hospitals (2012). J Infect, 2014; 69:266–277.
274.
LucastiC, PopescuI, RameshMK, et al.Comparative study of the efficacy and safety of ceftazidime/avibactam plus metronidazole versus meropenem in the treatment of complicated intra-abdominal infections in hospitalized adults: Results of a randomized, double-blind, Phase II trial. J Antimicrob Chemother, 2013; 68:1183–1192.
275.
MazuskiJE, GasinkLB, ArmstrongJ, et al.Efficacy and safety of ceftazidime-avibactam plus metronidazole versus meropenem in the treatment of complicated intra-abdominal infection: Results from a randomized, controlled, double-blind, phase 3 program. Clin Infect Dis, 2016; 62:1380–1389.
276.
ZhanelGG, LawsonCD, AdamH, et al.Ceftazidime-avibactam: A novel cephalosporin/β-lactamase inhibitor combination. Drugs, 2013; 73:159–177.
277.
Lagacé-WiensP, WalktyA, KarlowskyJA. Ceftazidime-avibactam: An evidence-based review of its pharmacology and potential use in the treatment of Gram-negative bacterial infections. Core Evid, 2014; 9:13–25.
278.
SaderHS, CastanheiraM, FlammRK, et al.Ceftazidime/avibactam tested against Gram-negative bacteria from intensive care unit (ICU) and non-ICU patients, including those with ventilator-associated pneumonia. Int J Antimicrob Agents, 2015; 46:53–59.
279.
SaderHS, CastanheiraM, MendesRE, et al.Ceftazidime-avibactam activity against multidrug-resistant Pseudomonas aeruginosa isolated in U.S. medical centers in 2012 and 2013. Antimicrob Agents Chemother, 2015; 59:3656–3659.
SykesRB, BonnerDP, BushK, GeorgopapadakouNH. Azthreonam (SQ 26,776), a synthetic monobactam specifically active against aerobic Gram-negative bacteria. Antimicrob Agents Chemother, 1982; 21:85–92.
282.
McWilliamsCS, CondonS, SchwartzRM, GinocchioCC. Incidence of extended-spectrum-β lactamase-producing Escherichia coli and Klebsiella pneumoniae isolates that test susceptible to cephalosporins and aztreonam by the revised CLSI breakpoints. J Clin Microbiol, 2014; 52:2653–2655.
De WaeleJJ, TelladoJM, AlderJ, et al.Randomised clinical trial of moxifloxacin versus ertapenem in complicated intra-abdominal infections: Results of the PROMISE study. Int J Antimicrobial Agents, 2013:41:57–64.
285.
SchultszC, GeerlingsS. Plasmid-mediated resistance in Enterobacteriaceae: Changing landscape and implications for therapy. Drugs, 2012; 72:1–16.
286.
ZhanelGG, WiebeR, DilayL, et al.Comparative review of the carbapenems. Drugs, 2007; 67:1027–1052.
LucastiC, JasovichA, UmehO, et al.Efficacy and tolerability of IV doripenem versus meropenem in adults with complicated intra-abdominal infection: A phase III, prospective, multicenter, randomized, double-blind, noninferiority study. Clin Ther, 2008; 30:868–883.
289.
RiceDA, KanigaK, LeeM, RedmanR. Activity of doripenem versus comparators in subjects with baseline bacteraemia in six pooled phase 3 clinical trials. Int J Antimicrob Agents, 2013; 41:388–392.
290.
CannavinoCR, Castaneda-RuizB, RedmanR, et al.Safety and tolerability of doripenem in hospitalized children with complicated intra-abdominal infection, complicated urinary tract infections and pneumonia. Pediatr Infect Dis J, 2015; 34:1264–1267.
Verwaest C; Belgian Multicenter Study Group. Meropenem versus imipenem/cilastatin as empirical monotherapy for serious bacterial infections in the intensive care unit. Clin Microbiol Infect, 2000; 6:294–302.
293.
SolomkinJS, WilsonSE, ChristouNV, et al.Results of a clinical trial of clinafloxacin versus imipenem/cilastatin for intraabdominal infections. Ann Surg, 2001; 233:79–87.
294.
FominP, BeuranM, GradauskasA, et al.Tigecycline is efficacious in the treatment of complicated intra-abdominal infections. Int J Surg, 2005; 3:35–47.
295.
OlivaME, RekhaA, YellinA, et al.A multicenter trial of the efficacy and safety of tigecycline versus imipenem/cilastatin in patients with complicated intra-abdominal infections. BMC Infect Dis, 2005; 5:88.
296.
ChenZ, WuJ, ZhangY, et al.Efficacy and safety of tigecycline monotherapy vs. imipenem/cilastatin in Chinese patients with complicated intra-abdominal infections: A randomized controlled trial. BMC Infect Dis, 2010; 10:217.
297.
BrismarB, MalmborgAS, TunevallG, et al.Piperacillin-tazobactam versus imipenem-cilastatin for treatment of intra-abdominal infections. Antimicrob Agents Chemother, 1992; 36:2766–2773.
298.
KiratisinP, ChongthaleongA, TanTY, et al.Comparative in vitro activity of carbapenems against major Gram-negative pathogens: Results of Asia-Pacific surveillance from the COMPACT II study. Int J Antimicrob Agents, 2012; 39:311–316.
299.
MuYP, LiuRU, WangLQ, et al.Moxifloxacin monotherapy for treatment of complicated intra-abdominal infections: A meta-analysis of randomised controlled trials. Int J Clin Pract, 2012; 66:210–217.
300.
GoldsteinEJ, SolomkinJS, CitronDM, AlderJD. Clinical efficacy and correlation of clinical outcomes with in vitro susceptibility for anaerobic bacteria in patients with complicated intra-abdominal infections treated with moxifloxacin. Clin Infect Dis, 2011; 53:1074–1080.
301.
CohnSM, LipsettPA, BuchmanTG, et al.Comparison of intravenous/oral ciprofloxacin plus metronidazole versus piperacillin/tazobactam in the treatment of complicated intraabdominal infections. Ann Surg, 2000; 232:254–262.
302.
MatthaiouDK, PeppasG, BliziotisIA, FalagasME. Ciprofloxacin/metronidazole versus β-lactam-based treatment of intra-abdominal infections: A meta-analysis of comparative trials. Int J Antimicrob Agents, 2006; 28:159–165.
303.
AdefurinA, SammonsH, Jacqz-AigrainE, ChoonaraI. Ciprofloxacin safety in paediatrics: A systematic review. Arch Dis Child, 2011; 96:874–880.
304.
BradleyJS, JacksonMA; Committee on Infectious Diseases; American Academy of Pediatrics. The use of systemic and topical fluoroquinolones. Pediatrics, 2011; 128:e1034–e1045.
305.
BradfordPA. Tigecycline: A first in class glycylcycline. Clin Microbiol Newsletter, 2004; 26:163–168.
306.
PrasadP, SunJ, DannerRL, NatansonC. Excess deaths associated with tigecycline after approval based on noninferiority trials. Clin Infect Dis, 2012; 54:1699–1709.
307.
TasinaE, HaidichAB, KokkaliS, ArvanitidouM. Efficacy and safety of tigecycline for the treatment of infectious diseases: A meta-analysis. Lancet Infect Dis, 2011; 11:834–844.
308.
YahavD, LadorA, PaulM, LeiboviciL. Efficacy and safety of tigecycline: A systematic review and meta-analysis. J Antimicrob Chemother, 2011; 66:1963–1971.
309.
VardakasKZ, RafailidisPI, FalagasME. Effectiveness and safety of tigecycline: Focus on use for approved indications. Clin Infect Dis, 2012; 54:1672–1674.
310.
McGovernPC, WibleM, El-TahtawyA, et al.All-cause mortality imbalance in the tigecycline phase 3 and 4 clinical trials. Int J Antimicrob Agents, 2013; 41:463–467.
311.
DenysGA, CallisterSM, DowzickyMJ. Antimicrobial susceptibility among gram-negative isolates collected in the USA between 2005 and 2011 as part of the Tigecycline Evaluation and Surveillance Trial (T.E.S.T.). Ann Clin Microbiol Antimicrob, 2013; 12:24.
312.
SaderHS, FarrellDJ, FlammRK, JonesRN. Variation in potency and spectrum of tigecycline activity against bacterial strains from U.S. medical centers since its approval for clinical use (2006 to 2012). Antimicrob Agents Chemother, 2014; 58:2274–2280.
313.
BassettiM, NicoliniL, RepettoE, et al.Tigecycline use in serious nosocomial infections: A drug use evaluation. BMC Infect Dis, 2010; 10:287.
314.
EckmannC, MontraversP, BassettiM, et al.Efficacy of tigecycline for the treatment of complicated intraabdominal infections in real-life clinical practice from five European observational studies. J Antimicrob Chemother, 2013; 68(Suppl 2):ii25–ii35.
315.
MasedaE, DenisSE, RiquelmeA, GilsanzF. Use of tigecycline in critically ill patients with serious nosocomial intra-abdominal infections. Rev Esp Quimioter, 2013; 26:56–63.
316.
QureshiZA, PatersonDL, PotoskiBA, et al.Treatment outcome of bacteremia due to KPC-producing Klebsiella pneumoniae: Superiority of combination antimicrobial regimens. Antimicrob Agents Chemother, 2012; 56:2108–2113.
317.
TzouvelekisLS, Markogiannakis, PsichogiouM, et al.Carbapenemases in Klebsiella pneumoniae and other Enterobacteriaceae: An evolving crisis of global dimensions. Clin Microbiol Rev, 2012; 25:682–707.
318.
KmeidJG, YoussefMM, KanafaniZA, KanjSS. Combination therapy for Gram-negative bacteria: What is the evidence?. Expert Rev Anti Infect Ther, 2013; 11:1355–1362.
319.
FraserJD, AguayoP, LeysCM, et al.A complete course of intravenous antibiotics vs a combination of intravenous and oral antibiotics for perforated appendicitis in children: A prospective, randomized trial. J Pediatr Surg, 2010; 45:1198–1202.
320.
RiceHE, BrownRL, GollinG, et al.Results of a pilot trial comparing prolonged intravenous antibiotics with sequential intravenous/oral antibiotics for children with perforated appendicitis. Arch Surg, 2001; 136:1391–1395.
321.
AldridgeKE, O'BrienM. In vitro susceptibilities of the Bacteroides fragilis group species: Change in isolation rates significantly affects overall susceptibility data. J Clin Microbiol, 2002; 40:4349–4352.
322.
DeshpandeA, PasupuletiV, ThotaP, et al.Community-associated Clostridium difficile infection and antibiotics: A meta-analysis. J Antimicrob Chemother, 2013; 68:1951–1961.
323.
OwensRCJr, DonskeyCJ, GaynesRP, et al.Antimicrobial-associated risk factors for Clostridium difficile infection. Clin Infect Dis, 2008; 46(Suppl 1):S19–S31.
324.
BillingtonEO, PhangSH, GregsonDB, et al.Incidence, risk factors, and outcomes for Enterococcus spp. blood stream infections: A population-based study. Int J Infect Dis, 2014; 26:76–82.
Fernández-HidalgoN, AlmiranteB, GavaldàJ, et al.Ampicillin plus ceftriaxone is as effective as ampicillin plus gentamicin for treating Enterococcus faecalis infective endocarditis. Clin Infect Dis, 2013; 56:1261–1268.
327.
NadlerEP, ReblockKK, FordHR, GainesBA. Monotherapy versus multi-drug therapy for the treatment of perforated appendicitis in children. Surg Infect (Larchmt), 2003; 4:327–333.
328.
NadlerEP, GainesBA. The Surgical Infection Society guidelines on antimicrobial therapy for children with appendicitis. Surg Infect (Larchmt), 2008; 9:75–83.
329.
BiedenbachDJ, BellJM, SaderHS, et al.Antimicrobial susceptibility of Gram-positive bacterial isolates from the Asia–Pacific region and an in vitro evaluation of the bactericidal activity of daptomycin, vancomycin, and teicoplanin: A SENTRY Program Report (2003–2004). Int J Antimicrob Agents, 2007; 30:143–149.
330.
ChatterjeeI, IredellJR, WoodsM, LipmanJ. The implications of enterococci for the intensive care unit. Crit Care Resusc, 2007; 9:69–75.
331.
McBrideSJ, UptonA, RobertsSA. Clinical characteristics and outcomes of patients with vancomycin-susceptible Enterococcus faecalis and Enterococcus faecium bacteraemia—a five-year retrospective review. Eur J Clin Microbiol Infect Dis, 2010; 29:107–114.
332.
Conde-EstévezD, GrauS, AlbanellJ, et al.Clinical characteristics and outcomes of patients with vancomycin-susceptible Enterococcus faecalis and Enterococcus faecium bacteraemia in cancer patients. Eur J Clin Microbiol Infect Dis, 2011; 30:103–108.
333.
SaderHS, WattersAA, FritscheTR, JonesRN. Daptomycin antimicrobial activity tested against methicillin-resistant staphylococci and vancomycin-resistant enterococci isolated in European medical centers (2005). BMC Infect Dis, 2007; 7:29.
334.
BradleyJS. Which antibiotic for resistant Gram-positives, and why?. J Infect, 2014; 68(Suppl 1):S63–S75.
335.
CattoirV, GiardJC. Antibiotic resistance in Enterococcus faecium clinical isolates. Expert Rev Anti Infect Ther, 2014; 12:239–248.
336.
BirminghamMC, RaynerCR, MeagherAK, et al.Linezolid for the treatment of multidrug-resistant, gram-positive infections: Experience from a compassionate-use program. Clin Infect Dis, 2003; 36:159–168.
337.
LenO, MontejoM, CerveraC, et al.Daptomycin is safe and effective for the treatment of gram-positive cocci infections in solid organ transplantation. Transpl Infect Dis, 2014; 16:532–538.
338.
BalliEP, VenetisCA, MiyakisS. Systematic review and meta-analysis of linezolid versus daptomycin for treatment of vancomycin-resistant enterococcal bacteremia. Antimicrob Agents Chemother, 2014; 58:734–739.
339.
ChuangYC, WangJT, LinHY, ChangSC. Daptomycin versus linezolid for treatment of vancomycin-resistant enterococcal bacteremia: Systematic review and meta-analysis. BMC Infect Dis, 2014; 14:687.
340.
FierobeL, DecréD, MùllerC, et al.Methicillin-resistant Staphylococcus aureus as a causative agent of postoperative intra-abdominal infection: Relation to nasal colonization. Clin Infect Dis, 1999; 29:1231–1238.
341.
SolomkinJS. Antibiotic resistance in postoperative infections. Crit Care Med, 2001; 29(Suppl 4):N97–N99.
342.
KobayashiM, MohriY, OhiM, et al.Risk factors for anastomotic leakage and favorable antimicrobial treatment as empirical therapy for intra-abdominal infection in patients undergoing colorectal surgery. Surg Today, 2014; 44:487–493.
343.
MohrJF, MurrayBE. Point: Vancomycin is not obsolete for the treatment of infection caused by methicillin-resistant Staphylococcus aureus. Clin Infect Dis, 2007:44:1536–1542.
344.
LiuC, BayerA, CosgroveSE, et al.Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children: Executive summary. Clin Infect Dis, 2011; 52:285–292.
345.
RiveraAM, BoucherHW. Current concepts in antimicrobial therapy against select gram-positive organisms: Methicillin-resistant Staphylococcus aureus, penicillin-resistant pneumococci, and vancomycin-resistant enterococci. Mayo Clin Proc, 2011; 86:1230–1243.
346.
SolomkinJS, BjornsonHS, CainzosM, et al.A consensus statement on empiric therapy for suspected gram-positive infections in surgical patients. Am J Surg, 2004; 187:134–145.
HolmesNE, TurnidgeJD, MunckhofWJ, et al.Antibiotic choice may not explain poorer outcomes in patients with Staphylococcus aureus bacteremia and high vancomycin minimum inhibitory concentrations. J Infect Dis, 2011; 204:340–347.
Wong-BeringerA, JooJ, TsedE, BeringerP. Vancomycin-associated nephrotoxicity: A critical appraisal of risk with high-dose therapy. Int J Antimicrob Agents, 2011; 37:95–101.
352.
van HalSJ, PatersonDL, LodiseTP. Systematic review and meta-analysis of vancomycin-induced nephrotoxicity associated with dosing schedules that maintain troughs between 15 and 20 milligrams per liter. Antimicrob Agents Chemother, 2013; 57:734–744.
353.
PletzMW, BurkhardtO, WelteT. Nosocomial methicillin-resistant Staphylococcus aureus (MRSA) pneumonia: Linezolid or vancomycin? – Comparison of pharmacology and clinical efficacy. Eur J Med Res, 2010; 15:507–513.
354.
McDaneldPM, SpoonerLM, MohrJF, BelliveauPP. Use of daptomycin to treat infections with methicillin-resistant Staphylococcus aureus isolates having vancomycin minimum inhibitory concentrations of 1.5 to 2 μg/mL. Ann Pharmacother, 2013; 47:1654–1665.
355.
BassettiM, BaguneidM, BouzaE, et al.European perspective and update on the management of complicated skin and soft tissue infections due to methicillin-resistant Staphylococcus aureus after more than 10 years of experience with linezolid. Clin Microbiol Infect, 2014; 20(Suppl 4):3–18.
356.
DoddsTJ, HawkeCI. Linezolid versus vancomycin for MRSA skin and soft tissue infections (systematic review and meta-analysis). ANZ J Surg, 2009; 79:629–635.
357.
BallyM, DendukuriN, SinclairA, et al.A network meta-analysis of antibiotics for treatment of hospitalised patients with suspected or proven meticillin-resistant Staphylococcus aureus infection. Int J Antimicrob Agents, 2012; 40:479–495.
HeW, ZhangY, ChenH, et al.Efficacy and safety of daptomycin for the treatment of infectious disease: A meta-analysis based on randomized controlled trials. J Antimicrob Chemother, 2014; 69:3181–3189.
360.
HamillRJ. Amphotericin B formulations: A comparative review of efficacy and toxicity. Drugs, 2013; 73:919–934.
361.
Mora-DuarteJ, BettsR, RotsteinC, et al.Comparison of caspofungin and amphotericin B for invasive candidiasis. N Engl J Med, 2002; 347:2020–2029.
362.
KuseER, ChetchotisakdP, da CunhaCA, et al.Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: A phase III randomised double-blind trial. Lancet, 2007; 369:1519–1527.
363.
Abele-HornM, KoppA, SternbergU, et al.A randomized study comparing fluconazole with amphotericin B/5-flucytosine for the treatment of systemic Candida infections in intensive care patients. Infection, 1996; 24:426–432.
364.
Gafter-GviliA, VidalL, GoldbergE, et al.Treatment of invasive candidal infections: Systematic review and meta-analysis. Mayo Clin Proc, 2008; 83:1011–1021.
365.
ReboliAC, RotsteinC, PappasPG, et al.Anidulafungin versus fluconazole for invasive candidiasis. N Engl J Med, 2007; 356:2472–2482.
366.
EggimannP, FrancioliP, BilleJ, et al.Fluconazole prophylaxis prevents intra-abdominal candidiasis in high-risk surgical patients. Crit Care Med, 1999; 27:1066–1072.
367.
Lass-FlörlC. Triazole antifungal agents in invasive fungal infections: A comparative review. Drugs, 2011; 71:2405–2419.
368.
FothergillAW, SuttonDA, McCarthyDI, WiederholdNP. Impact of new antifungal breakpoints on antifungal resistance in Candida species. J Clin Microbiol, 2014; 52:994–997.
369.
MalaniAN, KerrLE, KauffmanCA. Voriconazole: How to use this antifungal agent and what to expect. Semin Respir Crit Care Med, 2015; 36:786–795.
370.
KullbergBJ, SobelJD, RuhnkeM, et al.Voriconazole versus a regimen of amphotericin B followed by fluconazole for candidaemia in non-neutropenic patients: A randomised non-inferiority trial. Lancet, 2005; 366:1435–1442.
371.
Queiroz-TellesF, BerezinE, LevergerG, et al.Micafungin versus liposomal amphotericin B for pediatric patients with invasive candidiasis: Substudy of a randomized double-blind trial. Pediatr Infect Dis J, 2008; 27:820–826.
372.
SennL, EggimannP, KsontiniR, et al.Caspofungin for prevention of intra-abdominal candidiasis in high-risk surgical patients. Intensive Care Med, 2009; 35:903–908.
373.
KettDH, ShorrAF, ReboliAC, et al.Anidulafungin compared with fluconazole in severely ill patients with candidemia and other forms of invasive candidiasis: Support for the 2009 IDSA treatment guidelines for candidiasis. Crit Care, 2011; 15:R253.
374.
NeohCF, SlavinM, ChenSC, et al.Echinocandins in the treatment of candidaemia and invasive candidiasis: Clinical and economic perspectives. Int J Antimicrob Agents, 2014; 43:207–214.
375.
PappasPG, KauffmanCA, AndesD, et al.Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis, 2009; 48:503–535.
376.
SolomkinJS, ReinhartHH, DellingerEP, et al.Results of a randomized trial comparing sequential intravenous/oral treatment with ciprofloxacin plus metronidazole to imipenem/cilastatin for intra-abdominal infections. Ann Surg, 1996; 223:303–315.
377.
DonahuePE, SmithDL, YellinAE, et al.Trovafloxacin in the treatment of intra-abdominal infections: Results of a double-blind, multicenter comparison with imipenem/cilastatin. Am J Surg, 1998; 176(Suppl 6A):53S–61S.
378.
BuckRE, PriceKE. Cefadroxil, a new broad-spectrum cephalosporin. Antimicrob Agents Chemother, 1977; 11:324–330.
379.
NeuHC, FuKP. Cefaclor: In vitro spectrum of activity and beta-lactamase stability. Antimicrob Agents Chemother, 1978; 13:584–588.
380.
WiseR, AndrewsJM, AshbyJP, ThornberD. The in-vitro activity of cefpodoxime: A comparison with other oral cephalosporins. J Antimicrob Chemother, 1990; 25:541–550.
381.
BauernfeindA, JungwirthR. Antibacterial activity of cefpodoxime in comparison with cefixime, cefdinir, cefatamet, cefibuten, loracarbef, cefprozil, BAY 3522, cefuroxime, cefaclor, and cefadroxil. Infection, 1991; 19:353–362.
382.
ThornsberryC. Review of the in vitro antibacterial activity of cefprozil, a new oral cephalosporin. Clin Infect Dis, 1992; 14(Suppl 2):S189–S194.
383.
SchatzBS, KaravokirosKT, TaeubelMA, ItokazuGS. Comparison of cefprozil, cefpodoxime proxetil, loracarbef, cefixime, and ceftibuten. Ann Pharmacother, 1996; 30:258–268.
384.
ScottLJ, OrmrodD, GoaKL. Cefuroxime axetil: An updated review of its use in the management of bacterial infections. Drugs, 2001; 61:1455–1500.
385.
SaderHS, JonesRN. Cefdinir: An oral cephalosporin for the treatment of respiratory tract infections and skin and skin structure infections. Expert Rev Anti Infect Ther, 2007; 5:29–43.
386.
TaylorE, DevV, ShahD, et al.Complicated appendicitis: Is there a minimum intravenous antibiotic requirement? A prospective randomized trial. Am Surg, 2000; 66:887–890.
387.
GollinG, AbarbanellA, MooresD. Oral antibiotics in the management of perforated appendicitis in children. Am Surg, 2002; 68:1072–1074.
388.
AdibeOO, BarnabyK, DobiesJ, et al.Postoperative antibiotic therapy for children with perforated appendicitis: Long course of intravenous antibiotics versus early conversion to an oral regimen. Am J Surg, 2008; 195:141–143.
389.
MerlinoJI, MalangoniMA, SmithCM, LangeRL. Prospective randomized trials affect the outcomes of intraabdominal infection. Ann Surg, 2001; 233:859–866.
390.
WongPF, GilliamAD, KumarS, et al.Antibiotic regimens for secondary peritonitis of gastrointestinal origin in adults. Cochrane Database Syst Rev, 2005; 2:CD004539.
391.
BrookI. Microbiology and management of intra-abdominal infections in children. Pediatr Int, 2003; 45:123–129.
392.
CsendesA, BurdilesP, MaluendaF, et al.Simultaneous bacteriologic assessment of bile from gallbladder and common bile duct in control subjects and patients with gallstones and common duct stones. Arch Surg, 1996; 131:389–394.
393.
Guillet-CarubaC, CheikhelardA, GuilletM, et al.Bacteriologic epidemiology and empirical treatment of pediatric complicated appendicitis. Diagn Microbiol Infect Dis, 2011; 69:376–381.
394.
SchmittF, ClermidiP, DorsiM, et al.Bacterial studies of complicated appendicitis over a 20-year period and their impact on empirical antibiotic treatment. J Pediatr Surg, 2012; 47:2055–2062.
395.
Society for Healthcare Epidemiology of America, Infectious Diseases Society of America, Pediatric Infectious Diseases Society. Policy statement on antimicrobial stewardship by the Society for Healthcare Epidemiology of America (SHEA), the Infectious Diseases Society of America (IDSA), and the Pediatric Infectious Diseases Society (PIDS). Infect Control Hosp Epidemiol, 2012; 33:322–327.
396.
SkrupkyLP, TellorBR, MazuskiJE. Current strategies for the treatment of complicated intraabdominal infections. Expert Opin Pharmacother, 2013; 14:1933–1947.
397.
HawserSP, BouchillonSK, HobanDJ, et al.Incidence and antimicrobial susceptibility of Escherichia coli and Klebsiella pneumoniae with extended-spectrum β-lactamases in community- and hospital-associated intra-abdominal infections in Europe: Results of the 2008 study for Monitoring Antimicrobial Resistance Trends (SMART). Antimicrob Agents Chemother, 2010; 54:3043–3046.
398.
AnayaDA, NathensAB. Risk factors for severe sepsis in secondary peritonitis. Surg Infect (Larchmt), 2003; 4:355–362.
399.
FraserJD, AguayoP, SharpSW, et al.Physiologic predictors of postoperative abscess in children with perforated appendicitis: Subset analysis from a prospective randomized trial. Surgery, 2010; 147:729–732.
400.
NatarajaRM, TeagueWJ, GaleaJ, et al.Comparison of intraabdominal abscess formation after laparoscopic and open appendicectomies in children. J Pediatr Surg, 2012; 47:317–321.
401.
FallonSC, BrandtML, HassanSF, et al.Evaluating the effectiveness of a discharge protocol for children with advanced appendicitis. J Surg Res, 2013; 184:347–351.
402.
FrakkingFN, RottierWC, Dorigo-ZetsmaJW, et al.Appropriateness of empirical treatment and outcome in bacteremia caused by extended-spectrum-β-lactamase-producing bacteria. Antimicrob Agents Chemother, 2013; 57:3092–3099.
403.
TheunissenC, CherifiS, KarmaliR. Management and outcome of high-risk peritonitis: A retrospective survey 2005–2009. Int J Infect Dis, 2011; 15:e769–e773.
404.
JooEJ, KangCI, HaYE, et al.Impact of inappropriate empiric antimicrobial therapy on outcome in Pseudomonas aeruginosa bacteraemia: A stratified analysis according to sites of infection. Infection, 2011; 39:309–318.
405.
BrunkhorstFM, OppertM, MarxG, et al.Effect of empirical treatment with moxifloxacin and meropenem vs meropenem on sepsis-related organ dysfunction in patients with severe sepsis: A randomized trial. JAMA, 2012; 307:2390–2399.
406.
HuY, LiL, LiW, et al.Combination antibiotic therapy versus monotherapy for Pseudomonas aeruginosa bacteraemia: A meta-analysis of retrospective and prospective studies. Int J Antimicrob Agents, 2013; 42:492–496.
407.
ComettaA, BaumgartnerJD, LewD, et al.Prospective randomized comparison of imipenem monotherapy with imipenem plus netilmicin for treatment of severe infections in nonneutropenic patients. Antimicrob Agents Chemother, 1994; 38:1309–1313.
408.
KaffarnikMF, UrbanM, HoptUT, UtzolinoS. Impact of enterococcus on immunocompetent and immunosuppressed patients with perforation of the small or large bowel. Tech Health Care, 2012; 20:37–48.
409.
DowzickyMJ. Susceptibility to tigecycline and linezolid among gram-positive isolates collected in the United States as part of the Tigecycline Evaluation and Surveillance Trial (TEST) between 2004 and 2009. Clin Ther, 2011; 33:1964–1973.
410.
Alvarez-LermaF, GrauS, FerrándezO. Characteristics of doripenem: A new broad-spectrum antibiotic. Drug Des Devel Ther, 2009; 3:173–190.
411.
SuppliM, AabenhusR, HarboeZB, et al.Mortality in enterococcal bloodstream infections increases with inappropriate antimicrobial therapy. Clin Microbiol Infect, 2011; 17:1078–1083.
412.
DupontH, Paugam-BurtzC, Muller-SerieysC, et al.Predictive factors of mortality due to polymicrobial peritonitis with Candida isolation in peritoneal fluid in critically ill patients. Arch Surg, 2002; 137:1341–1346.
413.
SandvenP, QvistH, SkovlundE, et al.Significance of Candida recovered from intraoperative specimens in patients with intra-abdominal perforations. Crit Care Med, 2002; 30:541–547.
414.
KhouryW, SzoldO, SofferD, et al.Prophylactic fluconazole does not improve outcome in patients with purulent and fecal peritonitis due to lower gastrointestinal perforation. Am Surg, 2010; 76:197–202.
415.
BlotSI, VandewoudeaKH, De WaeleJJ. Candida peritonitis. Curr Opin Crit Care, 2007; 13:195–199.
416.
LeeSC, FungCP, ChenHY, et al.Candida peritonitis due to peptic ulcer perforation: Incidence rate, risk factors, prognosis and susceptibility to fluconazole and amphotericin B. Diagn Microbiol Infect Dis, 2002; 44:23–27.
417.
de RuiterJ, WeelJ, ManusamaE, et al.The epidemiology of intra-abdominal flora in critically ill patients with secondary and tertiary abdominal sepsis. Infection, 2009; 37:522–527.
418.
MontraversP, MiraJP, GangneuxJP, et al.A multicentre study of antifungal strategies and outcome of Candida spp. peritonitis in intensive-care units. Clin Microbiol Infect, 2011; 17:1061–1067.
419.
BorchJE, AndersenKE, Bindslev-JensenC. The prevalence of suspected and challenge-verified penicillin allergy in a university hospital population. Basic Clin Pharmacol Toxicol, 2006; 98:357–362.
420.
WongBB, KeithPK, WasermanS. Clinical history as a predictor of penicillin skin test outcome. Ann Allergy Asthma Immunol, 2006; 97:169–174.
421.
SodhiM, AxtellSS, CallahanJ, ShekarR. Is it safe to use carbapenems in patients with a history of allergy to penicillin?. J Antimicrob Chemother, 2004; 54:1155–1157.
422.
PrescottWAJr, KusmierskiKA. Clinical importance of carbapenem hypersensitivity in patients with self-reported and documented penicillin allergy. Pharmacotherapy, 2007; 27:137–142.
423.
EndimianiA, PatersonDL. Optimizing therapy for infections caused by Enterobacteriaceae producing extended-spectrum β-lactamases. Semin Respir Crit Care Med, 2007; 28:646–655.
424.
PitoutJD. Infections with extended-spectrum β-lactamase-producing Enterobacteriaceae: Changing epidemiology and drug treatment choices. Drugs, 2010; 70:313–333.
425.
ChopraT, MarchaimD, VeltmanJ, et al.Impact of cefepime therapy on mortality among patients with bloodstream infections caused by extended-spectrum-β-lactamase-producing Klebsiella pneumoniae and Escherichia coli. Antimicrob Agents Chemother, 2012; 56:3936–3942.
426.
HuangCC, ChenYS, TohHS, et al.Impact of revised CLSI breakpoints for susceptibility to third-generation cephalosporins and carbapenems among Enterobacteriaceae isolates in the Asia-Pacific region: Results from the Study for Monitoring Antimicrobial Resistance Trends (SMART), 2002–2010. Int J Antimicrob Agents, 2012; 40 (Suppl):S4–S10.
427.
LeeNY, LeeCC, HuangWH, et al.Cefepime therapy for monomicrobial bacteremia caused by cefepime-susceptible extended-spectrum beta-lactamase-producing Enterobacteriaceae: MIC matters. Clin Infect Dis, 2013; 56:488–495.
428.
Martinez-MartinezL, Hernandez-AllesS, AlbertiS, et al.In vivo selection of porin-deficient mutants of Klebsiella pneumoniae with increased resistance to cefoxitin and expanded-spectrum cephalosporins. Antimicrob Agents Chemother, 1996; 40:342–348.
429.
Nørskov-LauritsenN, MarchandinH, DowzickyMJ. Antimicrobial susceptibility of tigecycline and comparators against bacterial isolates collected as part of the TEST study in Europe (2004–2007). Int J Antimicrob Agents, 2009; 34:121–130.
430.
ParkYS, Adams-HaduchJM, ShuttKA, et al.Clinical and microbiologic characteristics of cephalosporin-resistant Escherichia coli at three centers in the United States. Antimicrob Agents Chemother, 2012; 56:1870–1876.
431.
HawserSP, BadalRE, BouchillonSK, et al.Monitoring the global in vitro activity of ertapenem against Escherichia coli from intra-abdominal infections: SMART 2002–2010. Int J Antimicrob Agents, 2013; 41:224–228.
432.
Lynch JPIII, ClarkNM, ZhanelGG. Evolution of antimicrobial resistance among Enterobacteriaceae (focus on extended spectrum β-lactamases and carbapenemases). Expert Opin Pharmacother, 2013; 14:199–210.
433.
ZimhonyO, ChmelnitskyI, BardensteinR, et al.Endocarditis caused by extended spectrum-β-lactamase-producing Klebsiella pneumoniae: Emergence of resistance to ciprofloxacin and piperacillin-tazobactam during treatment despite initial susceptibility. Antimicrob Agents Chemother, 2006; 50:3179–3182.
434.
NordmannP, NaasT, PoirelL. Global spread of carbapenemase-producing Enterobacteriaceae. Emerg Infect Dis, 2011; 17:1791–1798.
435.
CantónR, AkóvaM, CarmeliY, et al.Rapid evolution and spread of carbapenemases among Enterobacteriaceae in Europe. Clin Microbiol Infect, 2012; 18:413–431.
436.
TorerN, YorganciK, ElkerK, SayekI. Prognostic factors of the mortality of postoperative intraabdominal infections. Infection, 2010; 38:255–260.
437.
ChenYH, HsuehPR. Changing bacteriology of abdominal and surgical sepsis. Curr Opin Infect Dis, 2012; 25:590–595.
438.
SartelliM, VialeP, CatenaF, et al.2013 WSES guidelines for management of intra-abdominal infections. World J Emerg Surg, 2013; 8:3.
439.
KangCI, ChungDR, KoKS, et al.Clinical predictors for enterococcal bacteraemia in patients with bacteraemic intra-abdominal infections. Scand J Infect Dis, 2010; 42:817–820.
440.
DupontH, VaelC, Muller-SerieysC, et al.Prospective evaluation of virulence factors of enterococci isolated from patients with peritonitis: Impact on outcome. Diagn Microbiol Infect Dis, 2008; 60:247–253.
441.
ReikR, TenoverFC, KleinE, McDonaldLC. The burden of vancomycin-resistant enterococcal infections in US hospitals, 2003 to 2004. Diagn Microbiol Infect Dis, 2008; 62:81–85.
442.
GilmoreMS, LebretonF, van SchaikW. Genomic transition of enterococci from gut commensals to leading causes of multidrug-resistant hospital infection in the antibiotic era. Curr Opin Microbiol, 2013; 16:10–16.
443.
ZiakasPD, PliakosEE, ZervouFN, et al.MRSA and VRE colonization in solid organ transplantation: A meta-analysis of published studies. Am J Transplant, 2014; 14:1887–1894.
444.
ReinertRR, LowDE, RossiF, et al.Antimicrobial susceptibility among organisms from the Asia/Pacific Rim, Europe and Latin and North America collected as part of TEST and the in vitro activity of tigecycline. J Antimicrob Chemother, 2007; 60:1018–1029.
445.
DeshpandeLM, FritscheTR, MoetGJ, et al.Antimicrobial resistance and molecular epidemiology of vancomycin-resistant enterococci from North America and Europe: A report from the SENTRY antimicrobial surveillance program. Diag Microbiol Infect Dis, 2007; 58:163–170.
446.
FlorescuI, BeuranM, DimovR, et al.Efficacy and safety of tigecycline compared with vancomycin or linezolid for treatment of serious infections with methicillin-resistant Staphylococcus aureus or vancomycin-resistant enterococci: A Phase 3, multicentre, double-blind, randomized study. J Antimicrob Chemother, 2008; 62(Suppl 1):i17–i28.
447.
HeizmannWR, LöschmannPA, EckmannC. Clinical efficacy of tigecycline used as monotherapy or in combination regimens for complicated infections with documented involvement of multiresistant bacteria. Infection, 2015; 43:37–43.
448.
NathensAB, ChuPT, MarshallJC. Nosocomial infection in the surgical intensive care unit. Infect Dis Clin North Am, 1992; 6:657–675.
449.
Graham PLIII, LinSX, LarsonEL. A U.S. population-based survey of Staphylococcus aureus colonization. Ann Intern Med, 2006; 144:318–325.
450.
HarbarthS, SaxH, UckayI, et al.A predictive model for identifying surgical patients at risk of methicillin-resistant Staphylococcus aureus carriage on admission. J Am Coll Surg, 2008; 207:683–689.
451.
McKinnellJA, MillerLG, EellsSJ, et al.A systematic literature review and meta-analysis of factors associated with methicillin-resistant Staphylococcus aureus colonization at time of hospital or intensive care unit admission. Infect Control Hosp Epidemiol, 2013; 34:1077–1086.
452.
RybakM, LomaestroB, RotschaferJC, et al.Therapeutic monitoring of vancomycin in adult patients: A consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. Am J Health-Syst Pharm, 2009; 66:82–98.
453.
DentonM. Enterobacteriaceae. Int J Antimicrob Agents, 2007; 29(Suppl 3):S9–S22.
454.
AugustinP, Tran-DinhA, ValinN, et al.Pseudomonas aeruginosa post-operative peritonitis: Clinical features, risk factors, and prognosis. Surg Infect (Larchmt), 2013; 14:297–303.
455.
NordmannP, CuzonG, NaasT. The real threat of Klebsiella pneumoniae carbapenemase-producing bacteria. Lancet Infect Dis, 2009; 9:228–236.
456.
ZavasckiAP, CarvalhaesCG, PicãoRC, GalesAC. Multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii: Resistance mechanisms and implications for therapy. Expert Rev Anti Infect Ther, 2010; 8:71–93.
457.
CornagliaG, GiamarellouH, RossoliniGM. Metallo-β-lactamases: A last frontier for β-lactams?. Lancet Infect Dis, 2011; 11:381–393.
458.
DalhoffA. Global fluoroquinolone resistance epidemiology and implictions for clinical use. Interdiscip Perspect Infect Dis, 2012; 2012:976273.
459.
LiuYM, ChenYS, TohHS, et al.In vitro susceptibilities of non-Enterobacteriaceae isolates from patients with intra-abdominal infections in the Asia-Pacific region from 2003 to 2010: Results from the Study for Monitoring Antimicrobial Resistance Trends (SMART). Int J Antimicrob Agents, 2012; 40 (Suppl 1):S11–S17.
460.
CastanheiraM, DeshpandeLM, CostelloA, et al.Epidemiology and carbapenem resistance mechanisms of carbapenem-non-susceptible Pseudomonas aeruginosa collected during 2009–11 in 14 European and Mediterranean countries. J Antimicrob Chemother, 2014; 69:1804–1814.
461.
NamiasN, SamiianL, NinoD, et al.Incidence and susceptibility of pathogenic bacteria vary between intensive care units within a single hospital: Implications for empiric antibiotic strategies. J Trauma, 2000; 49:638–645.
462.
BinkleyS, FishmanNO, LaRosaLA, et al.Comparison of unit-specific and hospital-wide antibiograms: Potential implications for selection of empirical antimicrobial therapy. Infect Control Hosp Epidemiol, 2006; 27:682–687.
463.
KusterSP, RuefC, ZbindenR, et al.Stratification of cumulative antibiograms in hospitals for hospital unit, specimen type, isolate sequence and duration of hospital stay. J Antimicrob Chemother, 2008; 62:1451–1461.
464.
PatersonDL. Recommendation for treatment of severe infections caused by Enterobacteriaceae producing extended-spectrum β-lactamases (ESBLs). Clin Microbiol Infect, 2000:6:460–463.
465.
EndimianiA, LuzzaroF, PerilliM, et al.Bacteremia due to Klebsiella pneumoniae isolates producing the TEM-52 extended-spectrum β-lactamase: Treatment outcome of patients receiving imipenem or ciprofloxacin. Clin Infect Dis, 2004; 38:243–251.
466.
PatersonDL, KoWC, Von GottbergA, et al.Antibiotic therapy for Klebsiella pneumoniae bacteremia: Implications of production of extended-spectrum β-lactamases. Clin Infect Dis, 2004; 39:31–37.
467.
NguyenHM, ShierKL, GraberCJ. Determining a clinical framework for use of cefepime and β-lactam/β-lactamase inhibitors in the treatment of infections caused by extended-spectrum-β-lactamase-producing Enterobacteriaceae. J Antimicrob Chemother, 2014; 69:871–880.
468.
HiltyM, SendiP, SeiffertSN, et al.Characterisation and clinical features of Enterobacter cloacae bloodstream infections occurring at a tertiary care university hospital in Switzerland: Is cefepime adequate therapy?. Int J Antimicrob Agents, 2013; 41:236–249.
469.
CastanheiraM, MillsJC, CostelloSE, et al.Ceftazidime-avibactam activity tested against Enterobacteriaceae isolates from U.S. hospitals (2011 to 2013) and characterization of β-lactamase-producing strains. Antimicrob Agents Chemother, 2015; 59:3509–3517.
470.
YoshizumiA, IshiiY, AokiK, et al.In vitro susceptibility of characterized β-lactamase-producing Gram-negative bacteria isolated in Japan to ceftazidime-, ceftaroline-, and aztreonam-avibactam combinations. J Infect Chemother, 2015; 21:148–151.
471.
TumbarelloM, VialeP, ViscoliC, et al.Predictors of mortality in bloodstream infections caused by Klebsiella pneumoniae carbapenemase–producing K. pneumoniae: Importance of combination therapy. Clin Infect Dis, 2012; 55:943–950.
472.
FalagasME, LouridaP, PoulikakosP, et al.Antibiotic treatment of infections due to carbapenem-resistant Enterobacteriaceae: Systematic evaluation of the available evidence. Antimicrob Agents Chemother, 2014; 58:654–663.
473.
LeeCR, LeeJH, ParkKS, et al.Global dissemination of carbapenemase-producing Klebsiella pneumoniae: Epidemiology, genetic context, treatment options, and detection methods. Front Microbiol, 2016; 7:895.
474.
MagiorakosAP, SrinivasanA, CareyRB, et al.Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: An international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect, 2012; 18:268–281.
475.
MasedaE, MensaJ, ValíaJC, et al.Bugs, hosts and ICU environment: Countering pan-resistance in nosocomial microbiota and treating bacterial infections in the critical care setting. Rev Esp Quimioter, 2013; 26:312–331.
476.
GiamarellouH, PoulakouG. Multidrug-resistant Gram-negative infections: What are the treatment options?. Drugs, 2009; 69:1879–1901.
477.
BiswasS, BrunelJM, DubusJC, et al.Colistin: An update on the antibiotic of the 21st century. Expert Rev Anti Infect Ther, 2012; 10:917–934.
478.
DalfinoL, PuntilloF, MoscaA, et al.High-dose, extended-interval colistin administration in critically ill patients: Is this the right dosing strategy? A preliminary study. Clin Infect Dis, 2012; 54:1720–1726.
479.
VicariG, BauerSR, NeunerEA, LamSW. Association between colistin dose and microbiologic outcomes in patients with multidrug-resistant gram-negative bacteremia. Clin Infect Dis, 2013; 56:398–404.
480.
KaraiskosI, GiamarellouH. Multidrug-resistant and extensively drug-resistant Gram-negative pathogens: Current and emerging therapeutic approaches. Expert Opin Pharmacother, 2014; 15:1351–1370.
481.
KassamaliZ, JainR, DanzigerLH. An update on the arsenal for multidrug-resistant Acinetobacter infections: Polymyxin antibiotics. Int J Infect Dis, 2015; 30:125–132.
482.
BlumbergHM, JarvisWR, SoucieJM, et al.Risk factors for candidal bloodstream infections in surgical intensive care unit patients: The NEMIS prospective multicenter study. Clin Infect Dis, 2001; 33:177–186.
483.
LeleuG, AegerterP, GuidetB; Collège des Utilisateurs de Base de Données en Réanimation. Systemic candidiasis in intensive care units: A multicenter, matched-cohort study. J Crit Care, 2002; 17:168–175.
484.
PuzniakL, TeutschS, PowderlyW, PolishL. Has the epidemiology of nosocomial candidemia changed?. Infect Control Hosp Epidemiol, 2004; 25:628–633.
485.
PaphitouNI, Ostrosky-ZeichnerL, RexJH. Rules for identifying patients at increased risk for candidal infections in the surgical intensive care unit: Approach to developing practical criteria for systematic use in antifungal prophylaxis trials. Med Mycol, 2005; 43:235–243.
486.
LeónC, Ruiz-SantanaS, SaavedraP, et al.A bedside scoring system (“Candida score”) for early antifungal treatment in nonneutropenic critically ill patients with Candida colonization. Crit Care Med, 2006; 34:730–737.
487.
Ostrosky-ZeichnerL, SableC, SobelJ, et al.Multicenter retrospective development and validation of a clinical prediction rule for nosocomial invasive candidiasis in the intensive care setting. Eur J Clin Microbiol Infect Dis, 2007; 26:271–276.
488.
LeroyO, GangneuxJP, MontraversP, et al.Epidemiology, management, and risk factors for death of invasive Candida infections in critical care: A multicenter, prospective, observational study in France (2005–2006). Crit Care Med, 2009; 37:1612–1618.
489.
CarneiroHA, MavrakisA, MylonakisE. Candida peritonitis: An update on the latest research and treatments. World J Surg, 2011; 35:2650–2659.
490.
CalandraT, BilleJ, SchneiderR, et al.Clinical significance of Candida isolated from peritoneum in surgical patients. Lancet, 1989; 2:1437–1440.
491.
HsuFC, LinPC, ChiCY, et al.Prognostic factors for patients with culture-positive Candida infection undergoing abdominal surgery. J Microbiol Immunol Infect, 2009; 42:378–384.
492.
SolomkinJS, FlohrAB, QuiePG, SimmonsRL. The role of Candida in intraperitoneal infections. Surgery, 1980; 88:524–530.
493.
PittetD, MonodM, SuterPM, et al.Candida colonization and subsequent infections in critically ill surgical patients. Ann Surg, 1994; 220:751–758.
494.
SandvenP, GierckskyKE; NORGAS Group, and the Norwegian Yeast Study Group. Yeast colonization in surgical patients with intra-abdominal perforations. Eur J Clin Microbiol Infect Dis, 2001; 20:475–481.
495.
HoeraufA, HammerS, Müller-MyhsokB, RupprechtH. Intra-abdominal Candida infection during acute necrotizing pancreatitis has a high prevalence and is associated with increased mortality. Crit Care Med, 1998; 26:2010–2015.
496.
VegeSS, GardnerTB, ChariST, et al.Outcomes of intra-abdominal fungal vs. bacterial infections in severe acute pancreatitis. Am J Gastroenterol, 2009; 104:2065–2070.
497.
BlotSI, VandewoudeKH, HosteEA, ColardynFA. Effects of nosocomial candidemia on outcomes of critically ill patients. Am J Med, 2002; 113:480–485.
498.
MorrellM, FraserVJ, KollefMH. Delaying the empiric treatment of candida bloodstream infection until positive blood culture results are obtained: A potential risk factor for hospital mortality. Antimicrob Agents Chemother, 2005; 49:3640–3645.
499.
ShanYS, SyED, WangST, et al.Early presumptive therapy with fluconazole for occult Candida infection after gastrointestinal surgery. World J Surg, 2006; 30:119–126.
500.
HsuDI, NguyenM, NguyenL, et al.A multicentre study to evaluate the impact of timing of caspofungin administration on outcomes of invasive candidiasis in non-immunocompromised adult patients. J Antimicrob Chemother, 2010; 65:1765–1770.
501.
KollefM, MicekS, HamptonN, et al.Septic shock attributed to Candida infection: Importance of empiric therapy and source control. Clin Infect Dis, 2012; 54:1739–1746.
502.
BassettiM, MarchettiM, ChakrabartiA, et al.A research agenda on the management of intra-abdominal candidiasis: Results from a consensus of multinational experts. Intensive Care Med, 2013; 39:2092–2106.
503.
PeaF. Current pharmacological concepts for wise use of echinocandins in the treatment of Candida infections in septic critically ill patients. Expert Rev Ant Infect Ther, 2013; 11:989–997.
504.
PfallerMA, AndesDR, DiekemaDJ, et al.Epidemiology and outcomes of invasive candidiasis due to non-albicans species of Candida in 2,496 patients: Data from the Prospective Antifungal Therapy (PATH) registry 2004–2008. PLoS One, 2014; 9:e101510.
505.
PfallerMA, DiekemaDJ. Progress in antifungal susceptibility testing of Candida spp. by use of Clinical and Laboratory Standards Institute broth microdilution methods, 2010 to 2012. J Clin Microbiol, 2012; 50:2846–2856.
506.
BariePS, HydoLJ, ShouJ, et al.Influence of antibiotic therapy on mortality of critical surgical illness caused or complicated by infection. Surg Infect (Larchmt), 2005; 6:41–54.
507.
KumarA, RobertsD, WoodKE, et al.Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit Care Med, 2006; 34:1589–1596.
508.
GaieskiDF, MikkelsenME, BandRA, et al.Impact of time to antibiotics on survival in patients with severe sepsis or septic shock in whom early goal-directed therapy was initiated in the emergency department. Crit Care Med, 2010; 38:1045–1053.
509.
CoronaA, BertoliniG, LipmanJ, et al.Antibiotic use and impact on outcome from bacteraemic critical illness: The BActeraemia Study in Intensive Care (BASIC). J Antimicrob Chemother, 2010; 65:1276–1285.
510.
PuskarichMA, TrzeciakS, ShapiroNI, et al.Association between timing of antibiotic administration and mortality from septic shock in patients treated with a quantitative resuscitation protocol. Crit Care Med, 2011; 39:2066–2071.
511.
VilellaAL, SeifertCF. Timing and appropriateness of initial antibiotic therapy in newly presenting septic patients. Am J Emerg Med, 2014; 32:7–13.
512.
RyooSM, KimWY, SohnCH, et al.Prognostic value of timing of antibiotic administration in patients with septic shock treated with early quantitative resuscitation. Am J Med Sci, 2015; 349:328–333.
513.
MangramAJ, HoranTC, PearsonML, et al.Guideline for prevention of surgical site infection, 1999. Infect Cont Hosp Epidemiol, 1999; 20:250–278.
514.
EngelmanR, ShahianD, SheminR, et al.The Society of Thoracic Surgeons Practice Guideline Series: Antibiotic prophylaxis in cardiac surgery, part II: Antibiotic choice. Ann Thorac Surg, 2007; 83:1569–1576.
515.
AndersonDJ, KayeKS, ClassenD, et al.Strategies to prevent surgical site infections in acute care hospitals. Infect Cont Hosp Epidemiol, 2008; 29 (Suppl 1):S51–S61.
516.
ClassenDC, EvansRS, PersotnikSL, et al.The timing of prophylactic administration of antibiotics and the risk of surgical-wound infection. N Engl J Med, 1992; 326:281–286.
517.
GareyKW, DaoT, ChenH, et al.Timing of vancomycin prophylaxis for cardiac surgery patients and the risk of surgical site infections. J Antimicrob Chemother, 2006; 58:645–650.
518.
van KasterenME, ManniënJ, OttA, et al.Antibiotic prophylaxis and the risk of surgical site infections following total hip arthroplasty: Timely administration is the most important factor. Clin Infect Dis, 2007; 44:921–927.
519.
WeberWP, MartiWR, ZwahlenM, et al.The timing of surgical antimicrobial prophylaxis. Ann Surg, 2008; 247:918–926.
520.
SteinbergJP, BraunBI, HellingerWC, et al.Timing of antimicrobial prophylaxis and the risk of surgical site infections: Results from the Trial to Reduce Antimicrobial Prophylaxis Errors. Ann Surg, 2009; 250:10–16.
521.
ZanettiG, GiardinaR, PlattR. Intraoperative redosing of cefazolin and risk for surgical site infection in cardiac surgery. Emerg Infect Dis, 2001; 7:828–831.
522.
MoritaS, NishishoI, NomuraT, et al.The significance of the intraoperative repeated dosing of antimicrobials for preventing surgical wound infection in colorectal surgery. Surg Today, 2005; 35:732–738.
BruntonLL, ChabnerBA, KnollmannBC (eds). Goodman and Gilman's The Pharmacological Basis of Therapeutics, 12th ed. New York: McGraw-Hill Medical, 2011.
525.
MuellerEW, BoucherBA. The use of extended-interval aminoglycoside dosing strategies for the treatment of moderate-to-severe infections encountered in critically ill surgical patients. Surg Infect (Larchmt), 2009; 10:563–570.
526.
PeaF, VialeP. Bench-to-bedside review: Appropriate antibiotic therapy in severe sepsis and septic shock—does the dose matter?. Crit Care, 2009; 13:214.
527.
EylerRF, MuellerBA. Antibiotic dosing in critically ill patients with acute kidney injury. Nat Rev Nephrol, 2011; 7:226–235.
528.
RobertsJA, JoyntGM, ChoiGY, et al.How to optimise antimicrobial prescriptions in the Intensive Care Unit: Principles of individualised dosing using pharmacokinetics and pharmacodynamics. Int J Antimicrob Agents, 2012; 39:187–192.
529.
LuytCE, BréchotN, TrouilletJL, ChastreJ. Antibiotic stewardship in the intensive care unit. Crit Care, 2014; 18:480.
530.
HoVP, JenkinsSG, AfanehCI, et al.Use of meropenem by continuous infusion to treat a patient with a Bla(kpc-2)-positive Klebsiella pneumoniae blood stream infection. Surg Infect, 2011; 12:325–327.
531.
TacconeFS, CottonF, RoisinS, et al.Optimal meropenem concentrations to treat multidrug-resistant Pseudomonas aeruginosa septic shock. Antimicrob Agents Chemother, 2012; 56:2129–2131.
532.
TacconeFS, LaterrePF, DugernierT, et al.Insufficient β-lactam concentrations in the early phase of severe sepsis and septic shock. Crit Care, 2010; 14:R126.
533.
CockcroftDW, GaultMH. Prediction of creatinine clearance from serum creatinine. Nephron, 1976; 16:31–41.
534.
PatelN, ScheetzMH, DrusanoGL, LodiseTP. Determination of antibiotic dosage adjustments in patients with renal impairment: Elements for success. J Antimicrob Chemother, 2010; 65:2285–2290.
535.
BrownDL, MasselinkAJ, LallaCD. Functional range of creatinine clearance for renal drug dosing: A practical solution to the controversy of which weight to use in the Cockcroft-Gault equation. Ann Pharmacother, 2013; 47:1039–1044.
CarlierM, DumoulinA, JanssenA, et al.Comparison of different equations to assess glomerular filtration in critically ill patients. Intensive Care Med, 2015; 41:427–435.
538.
ChoiG, GomersallCD, TianQ, et al.Principles of antibacterial dosing in continuous renal replacement therapy. Crit Care Med, 2009; 37:2268–2282.
539.
GilbertB, RobbinsP, LivorneseLLJr. Use of antibacterial agents in renal failure. Infect Dis Clin North Am, 2009; 23:899–924.
540.
HeintzBH, MatzkeGR, DagerWE. Antimicrobial dosing concepts and recommendations for critically ill adult patients receiving continuous renal replacement therapy or intermittent hemodialysis. Pharmacotherapy, 2009; 29:562–577.
541.
UlldemolinsM, RobertsJA, LipmanJ, RelloJ. Antibiotic dosing in multiple organ dysfunction syndrome. Chest, 2011; 139:1210–1220.
542.
HalilovicJ, HeintzBH. Antibiotic dosing in cirrhosis. Am Health Syst Pharm, 2014; 71:1621–1634.
543.
BeardenDT, RodvoldKA. Dosage adjustments for antibacterials in obese patients: Applying clinical pharmacokinetics. Clin Pharmacokinet, 2000; 38:415–426.
544.
ErstadBL. Dosing of medications in morbidly obese patients in the intensive care unit setting. Intensive Care Med, 2004; 30:18–32.
HanleyMJ, AbernethyDR, GreenblattDJ. Effect of obesity on the pharmacokinetics of drugs in humans. Clin Pharamacokinet, 2010; 49:71–87.
547.
JainR, ChungSM, KhuranaM, et al.Implications of obesity for drug therapy: Limitations and challenges. Clin Pharmacol Ther, 2011; 90:77–89.
548.
JansonB, ThurskyK. Dosing of antibiotics in obesity. Curr Opin Infect Dis, 2012; 25:634–649.
549.
VerhaveJC, FeslerP, RibsteinJ, et al.Estimation of renal function in subjects with normal serum creatinine levels: Influence of age and body mass index. Am J Kidney Dis, 2005; 46:233–241.
550.
SalazarDE, CorcoranGB. Predicting creatinine clearance and renal drug clearance in obese patients from estimated fat-free body mass. Am J Med, 1988; 84:1053–1060.
551.
SniderRD, KruseJA, BanderJJ, DunnGH. Accuracy of estimated creatinine clearance in obese patients with stable renal function in the intensive care unit. Pharmacotherapy, 1995; 15:747–753.
552.
BauerLA, BlouinRA, GriffenWOJr, et al.Amikacin pharmacokinetics in morbidly obese patients. Am J Hosp Pharm, 1980; 37:519–522.
553.
BauerLA, EdwardsWAD, DellingerEP, SimonowitzDA. Influence of weight on aminoglycoside pharmacokinetics in normal weight and morbidly obese patients. Eur J Clin Pharmacol, 1983; 24:643–647.
554.
LeaderWG, TsubakiT, ChandlerMH. Creatinine-clearance estimates for predicting gentamicin pharmacokinetic values in obese patients. Am J Hosp Pharm, 1994; 51:2125–2130.
555.
TraynorAM, NafzigerAN, BertinoJSJr. Aminoglycoside dosing weight correction factors for patients of various body sizes. Antimicrob Agents Chemother, 1995; 39:545–548.
556.
PayneKD, Hall RGII. Dosing of antibacterial agents in obese adults: Does one size fit all?. Expert Rev Anti Infect Ther, 2014; 12:829–854.
557.
YukJ, NightingaleCH, SweeneyK, et al.Pharmacokinetics of nafcillin in obesity. J Infect Dis, 1988; 157:1088–1089.
558.
ChenM, NafzigerAN, DrusanoGL, et al.Comparative pharmacokinetics and pharmacodynamic target attainment of ertapenem in normal-weight, obese, and extremely obese adults. Antimicrob Agents Chemother, 2006; 50:1222–1227.
559.
NewmanD, ScheetzMH, AdeyemiOA, et al.Serum piperacillin/tazobactam pharmacokinetics in a morbidly obese individual. Ann Pharmacother, 2007; 41:1734–1739.
560.
BarbourA, SchmidtS, RoutWR, et al.Soft tissue penetration of cefuroxime determined by clinical microdialysis in morbidly obese patients undergoing abdominal surgery. Int J Antimicrob Agents, 2009; 34:231–235.
561.
TomaO, SuntrupP, StefanescuA, et al.Pharmacokinetics and tissue penetration of cefoxitin in obesity: Implications for risk of surgical site infection. Anesth Analg, 2011; 113:730–737.
562.
van KralingenS, TaksM, DiepstratenJ, et al.Pharmacokinetics and protein binding of cefazolin in morbidly obese patients. Eur J Clin Pharmacol, 2011; 67:985–992.
563.
RobertsJA, LipmanJ. Optimal doripenem dosing simulations in critically ill nosocomial pneumonia patients with obesity, augmented renal clearance, and decreased bacterial susceptibility. Crit Care Med, 2013; 41:489–495.
564.
CaldwellJB, NilsenAK. Intravenous ciprofloxacin dosing in a morbidly obese patient. Ann Pharmacother, 1994; 28:806.
565.
HollensteinUM, BrunnerM, SchmidR, MüllerM. Soft tissue concentrations of ciprofloxacin in obese and lean subjects following weight-adjusted dosing. Int J Obes Relat Metab Disord, 2001; 25:354–358.
566.
UtrupTR, MuellerEW, HealyDP, et al.High-dose ciprofloxacin for serious gram-negative infection in an obese, critically ill patient receiving continuous venovenous hemodiafiltration. Ann Pharmacother, 2010; 44:1660–1664.
567.
CookAM, MartinC, AdamsVR, MoreheadRS. Pharmacokinetics of intravenous levofloxacin administered at 750 milligrams in obese adults. Antimicrob Agents Chemother, 2011; 55:3240–3243.
568.
KeesMG, WeberS, KeesF, HorbachT. Pharmacokinetics of moxifloxacin in plasma and tissue of morbidly obese patients. J Antimicrob Chemother, 2011; 66:2330–2335.
SteinGE, SchooleySL, PeloquinCA, et al.Pharmacokinetics and pharmacodynamics of linezolid in obese patients with cellulitis. Ann Pharmacother, 2005; 39:427–432.
571.
PuzniakLA, MorrowLE, HuangDB, BarretoJN. Impact of weight on treatment efficacy and safety in complicated skin and skin structure infections and nosocomial pneumonia caused by methicillin-resistant Staphylococcus aureus. Clin Ther, 2013; 35:1557–1570.
572.
DvorchikBH, DamphousseD. The pharmacokinetics of daptomycin in moderately obese, morbidly obese, and matched nonobese subjects. J Clin Pharmacol, 2005; 45:48–56.
573.
PaiMP, NorenbergJP, AndersonT, et al.Influence of morbid obesity on the single-dose pharmacokinetics of daptomycin. Antimicrob Agents Chemother, 2007; 51:2741–2747.
574.
ZakrisonTL, HilleDA, NamiasN. Effect of body mass index on treatment of complicated intra-abdominal infections in hospitalized adults: Comparison of ertapenem with piperacillin-tazobactam. Surg Infect, 2012; 13:38–42.
575.
DietchZC, DuaneTM, CookCH, et al.Obesity is not associated with antimicrobial treatment failure for intra-abdominal infection. Surg Infect (Larchmt), 2016; 17:412–421.
576.
RobertsJA, LipmanJ. Antibacterial dosing in intensive care. Pharmacokinetics, degree of disease and pharmacodynamics of sepsis. Clin Pharmacokinet, 2006; 45:755–773.
577.
McKinnonPS, PaladinoJA, SchentagJJ. Evaluation of area under the inhibitory curve (AUIC) and time above the minimum inhibitory concentration (T>MIC) as predictors of outcome for cefepime and ceftazidime in serious bacterial infections. Int J Antimicrob Agents, 2008; 31:345–351.
578.
RobertsJA, LipmanJ, BlotS, RelloJ. Better outcomes through continuous infusion of time-dependent antibiotics to critically ill patients?. Curr Opin Crit Care, 2008; 14:390–396.
579.
FalagasME, TansarliGS, IkawaK, VardakasKZ. Clinical outcomes with extended or continuous versus short-term intravenous infusion of carbapenems and piperacillin/tazobactam: A systematic review and meta-analysis. Clin Infect Dis, 2013; 56:272–82.
580.
ShiuJ, WangE, TejaniAM, WasdellM. Continuous versus intermittent infusions of antibiotics for the treatment of severe acute infections. Cochrane Database Syst Rev, 2013:3; CD008481.
581.
SeguinP, VerdierMC, ChanavazC, et al.Plasma and peritoneal concentration following continuous infusion of cefotaxime in patients with secondary peritonitis. J Antimicrob Chemother, 2009; 63:564–567.
582.
RobertsJA, WebbS, PatersonD, et al.A systematic review on clinical benefits of continuous administration of β-lactam antibiotics. Crit Care Med, 2009; 37:2071–2078.
583.
DulhuntyJM, RobertsJA, DavisJS, et al.A multicenter randomized trial of continuous versus intermittent β-lactam infusion in severe sepsis. Am J Respir Crit Care Med, 2015; 192:1298–1305.
584.
LauWK, MercerD, ItaniKM, et al.Randomized, open-label, comparative study of piperacillin-tazobactam administered by continuous infusion versus intermittent infusion for treatment of hospitalized patients with complicated intra-abdominal infection. Antimicrob Agents Chemother, 2006; 50:3556–3561.
585.
LiC, KutiJL, NightingaleCH, et al.Population pharmacokinetics and pharmacodynamics of piperacillin/tazobactam in patients with complicated intra-abdominal infection. J Antimicrob Chemother, 2005; 56:388–395.
586.
RiceLB. The Maxwell Finland Lecture: For the duration—Rational antibiotic administration in an era of antimicrobial resistance and Clostridium difficile. Clin Infect Dis, 2008; 46:491–496.
587.
NordbackI, SandJ, SaaristoR, PaajanenH. Early treatment with antibiotics reduces the need for surgery in acute necrotizing pancreatitis—a single-center randomized study. J Gastrointest Surg, 2001; 5:113–118.
588.
IsenmannR, RünziM, KronM, et al.Prophylactic antibiotic treatment in patients with predicted severe acute pancreatitis: A placebo-controlled, double-blind trial. Gastroenterology, 2004; 126:997–1004.
589.
DellingerEP, TelladoJM, SotoNE, et al.Early antibiotic treatment for severe acute necrotizing pancreatitis: A randomized, double-blind, placebo-controlled study. Ann Surg, 2007; 245:674–683.
590.
RøkkeO, HarbitzTB, LiljedalJ, et al.Early treatment of severe pancreatitis with imipenem: A prospective randomized clinical trial. Scand J Gastroenterol, 2007; 42:771–776.
591.
XueP, DengLH, ZhangZD, et al.Effect of antibiotic prophylaxis on acute necrotizing pancreatitis: Results of a randomized controlled trial. J Gastroenterol Hepatol, 2009; 24:736–742.
592.
García-BarrasaA, BorobiaFG, PallaresR, et al.A double-blind, placebo-controlled trial of ciprofloxacin prophylaxis in patients with acute necrotizing pancreatitis. J Gastrointest Surg, 2009; 13:768–774.
593.
MazakiT, IshiiY, TakayamaT. Meta-analysis of prophylactic antibiotic use in acute necrotizing pancreatitis. Br J Surg, 2006; 93:674–684.
594.
BaiY, GaoJ, ZouDW, LiZS. Prophylactic antibiotics cannot reduce infected pancreatic necrosis and mortality in acute necrotizing pancreatitis: Evidence from a meta-analysis of randomized controlled trials. Am J Gastroenterol, 2008; 103:104–110.
595.
JafriNS, MahidSS, IdsteinSR, et al.Antibiotic prophylaxis is not protective in severe acute pancreatitis: A systematic review and meta-analysis. Am J Surg, 2009; 197:806–813.
596.
VillatoroE, MullaM, LarvinM. Antibiotic therapy for prophylaxis against infection of pancreatic necrosis in acute pancreatitis. Cochrane Database Syst Rev, 2010; 5:CD002941.
597.
WittauM, MayerB, ScheeleJ, et al.Systematic review and meta-analysis of antibiotic prophylaxis in severe acute pancreatitis. Scand J Gastroenterol, 2011; 46:261–270.
598.
JiangK, HuangW, YangXN, XiaQ. Present and future of prophylactic antibiotics for severe acute pancreatitis. World J Gastroenterol, 2012; 18:279–284.
599.
LimCL, LeeW, LiewYX, et al.Role of antibiotic prophylaxis in necrotizing pancreatitis: A meta-analysis. J Gastrointest Surg, 2015; 19:480–491.
600.
DambrauskasZ, GulbinasA, PundziusJ, BarauskasG. Meta-analysis of prophylactic parenteral antibiotic use in acute necrotizing pancreatitis. Medicina (Kaunas), 2007; 43:291–300.
601.
XuT, CaiQ. Prophylactic antibiotic treatment in acute necrotizing pancreatitis: Results from a meta-analysis. Scand J Gastroenterol, 2008; 43:1249–1258.
602.
HartPA, BechtoldML, MarshallJB, et al.Prophylactic antibiotics in necrotizing pancreatitis: A meta-analysis. South Med J, 2008; 101:1126–1131.
603.
YaoL, HuangX, LiY, et al.Prophylactic antibiotics reduce pancreatic necrosis in acute necrotizing pancreatitis: A meta-analysis of randomized trials. Dig Surg, 2010; 27:442–449.
604.
de VriesAC, BesselinkMGH, BuskensE, et al.Randomized controlled trials of antibiotic prophylaxis in severe acute pancreatitis: Relationship between methodological quality and outcome. Pancreatology, 2007; 7:531–538.
605.
HjernF, JosephsonT, AltmanD, et al.Conservative treatment of acute colonic diverticulitis: Are antibiotics always mandatory?. Scand J Gastroenterol, 2007; 42:41–47.
606.
de KorteN, KuyvenhovenJP, van der PeetDL, et al.Mild colonic diverticulitis can be treated without antibiotics. A case-control study. Colorectal Dis, 2012; 14:325–330.
607.
ChabokA, PahlmanL, HjernF, et al.Randomized clinical trial of antibiotics in acute uncomplicated diverticulitis. Br J Surg, 2012; 99:532–539.
McDonaldM, GrabschE, MarshallC, ForbesA. Single- versus multiple-dose antimicrobial prophylaxis for major surgery: A systematic review. Aust N Z J Surg, 1998; 68:388–396.
610.
FonsecaSN, KunzleSR, JunqueiraMJ, et al.Implementing 1-dose antibiotic prophylaxis for prevention of surgical site infection. Arch Surg, 2006; 141:1109–1114.
611.
FabianTC, CroceMA, PayneLW, et al.Duration of antibiotic therapy for penetrating abdominal trauma: A prospective trial. Surgery, 1992; 112:788–794.
612.
BozorgzadehA, PizziWF, BariePS, et al.The duration of antibiotic administration in penetrating abdominal trauma. Am J Surg, 1999; 177:125–131.
613.
KirtonOC, O'NeillPA, KestnerM, TortellaBJ. Perioperative antibiotic use in high-risk penetrating hollow viscus injury: A prospective randomized, double-blind, placebo-control trial of 24 hours versus 5 days. J Trauma, 2000; 49:822–832.
614.
MuiLM, NgCS, WongSK, et al.Optimum duration of prophylactic antibiotics in acute non-perforated appendicitis. ANZ J Surg, 2005; 75:425–428.
615.
RegimbeauJM, FuksD, PautratK, et al.Effect of postoperative antibiotic administration on postoperative infection following cholecystectomy for acute calculous cholecystitis: A randomized clinical trial. JAMA, 2014; 312:145–154.
616.
AndåkerL, HöjerH, KihlströmE, LindhagenJ. Stratified duration of prophylactic antimicrobial treatment in emergency abdominal surgery. Metronidazole-fosfomycin vs. metronidazole-gentamicin in 381 patients. Acta Chir Scand, 1987; 153:185–192.
617.
ScheinM, AssaliaA, BachusH. Minimal antibiotic therapy after emergency abdominal surgery: A prospective study. Br J Surg, 1994; 81:989–991.
618.
GleisnerAL, ArgentaR, PimentelM, et al.Infective complications according to duration of antibiotic treatment in acute abdomen. Int J Infect Dis, 2004; 8:155–162.
619.
HughesMJ, HarrisonE, Paterson-BrownS. Post-operative antibiotics after appendectomy and post-operative abscess development: A retrospective analysis. Surg Infect (Larchmt), 2013; 14:56–61.
620.
van RossemCC, SchreinemacherMH, TreskesK, et al.Duration of antibiotic treatment after appendicectomy for acute complicated appendicitis. Br J Surg, 2014; 101:715–719.
621.
HedrickTL, EvansHL, SmithRL, et al.Can we define the ideal duration of antibiotic therapy?. Surg Infect (Larchmt), 2006; 7:419–432.
622.
RiccioLM, PopovskyKA, HranjecT, et al.Association of excessive duration of antibiotic therapy for intra-abdominal infection with subsequent extra-abdominal infection and death: a study of 2,552 consecutive infections. Surg Infect (Larchmt), 2014; 15:41–424.
623.
BasoliA, ChirlettiP, CirinoE, et al.A prospective, double-blind, multicenter, randomized trial comparing ertapenem 3 vs ≥5 days in community-acquired intraabdominal infection. J Gastrointest Surg, 2008; 12:592–600.
624.
LennardES, MinshewBH, DellingerEP, WertzM. Leukocytosis at termination of antibiotic therapy: Its importance for intra-abdominal sepsis. Arch Surg, 1980; 115:918–921.
625.
LennardES, DellingerEP, WertzMJ, MinshewBH. Implications of leukocytosis and fever at conclusion of antibiotic therapy for intra-abdominal sepsis. Ann Surg, 1982; 195:19–24.
626.
DanemanN, ShoreK, PintoR, FowlerR. Antibiotic treatment duration for bloodstream infections in critically ill patients: A national survey of Canadian infectious diseases and critical care specialists. Int J Antimicrob Agents, 2011; 38:480–485.
627.
HaveyTC, FowlerRA, PintoR, et al.Duration of antibiotic therapy for critically ill patients with bloodstream infections: A retrospective cohort study. Can J Infect Dis Med Microbiol, 2013; 24:129–137.
628.
HaveyTC, FowlerRA, DanemanN. Duration of antibiotic therapy for bacteremia: A systematic review and meta-analysis. Crit Care, 2011; 15:R267.
629.
VisserMR, BosschaK, OlsmanJ, et al.Predictors of recurrence of fulminant bacterial peritonitis after discontinuation of antibiotics in open management of the abdomen. Eur J Surg, 1998; 164:825–829.
630.
DoughertySH. Antimicrobial culture and susceptibility testing has little value for routine management of secondary bacterial peritonitis. Clin Infect Dis, 1997; 25 (Suppl 2):S258–S261.
631.
LeoneM, BourgoinA, CambonS, et al.Empirical antimicrobial therapy of septic shock patients: Adequacy and impact on the outcome. Crit Care Med, 2003; 31:462–467.
632.
MorelJ, CasoettoJ, JospéR, et al.De-escalation as part of a global strategy of empiric antibiotherapy management. A retrospective study in a medico-surgical intensive care unit. Crit Care, 2010; 14:R225.
633.
MontraversP, DupontH, GauzitR, et al.Strategies of initiation and streamlining of antibiotic therapy in 41 French intensive care units. Crit Care, 2011; 15:R17.
634.
DubrovskayaY, PapadopoulosJ, ScipioneMR, et al.Antibiotic stewardship for intra-abdominal infections: Early impact on antimicrobial use and patient outcomes. Infect Cont Hosp Epidemiol, 2012; 33:427–429.
635.
HeenenS, JacobsF, VincentJL. Antibiotic strategies in severe nosocomial sepsis: Why do we not de-escalate more often?. Crit Care Med, 2012; 40:1404–1409.
636.
GonzalezL, CravoisyA, BarraudD, et al.Factors influencing the implementation of antibiotic de-escalation and impact of this strategy in critically ill patients. Crit Care, 2013; 17:R140.
637.
Paugam-BurtzC, DupontH, MarmuseJP, et al.Daily organ-system failure for diagnosis of persistent intra-abdominal sepsis after postoperative peritonitis. Intensive Care Med, 2002; 28:594–598.
638.
NovotnyAR, EmmanuelK, HueserN, et al.Procalcitonin ratio indicates successful surgical treatment of abdominal sepsis. Surgery, 2009; 145:20–26.
639.
BariePS, WilliamsMD, McCollamJS, et al.Benefit/risk profile of drotrecogin alfa (activated) in surgical patients with severe sepsis. Am J Surg, 2004; 188:212–220.
640.
SirinekKR. Diagnosis and treatment of intra-abdominal abscesses. Surg Infect (Larchmt), 2000; 1:31–38.
641.
LeeMJ. Non-traumatic abdominal emergencies: Imaging and intervention in sepsis. Eur Radiol, 2002; 12:2172–2179.
642.
MeesonS, AlveyCM, GoldingSJ. Justifying multidetector CT in abdominal sepsis: Time for review?. Br J Radiol, 2009; 82:190–197.
643.
GoHL, BaarslagHJ, VermeulenH, et al.A comparative study to validate the use of ultrasonography and computed tomography in patients with post-operative intra-abdominal sepsis. Eur J Radiol, 2005; 54:383–387.
644.
LinCM, HungGU, ChaoTH, et al.The limited use of ultrasound in the detection of abdominal abscesses in patients after colorectal surgery: Compared with gallium scan and computed tomography. Hepatogastroenterology, 2005; 52:79–81.
645.
BaderFG, SchröderM, KujathP, et al.Diffuse postoperative peritonitis—value of diagnostic parameters and impact of early indication for relaparotomy. Eur J Med Res, 2009; 14:491–496.
646.
AllenBC, BarnhartH, BashirM, et al.Diagnostic accuracy of intra-abdominal fluid collection characterization in the era of multidetector computed tomography. Am Surg, 2012; 78:185–189.
647.
GnanntR, FischerMA, BaechlerT, et al.Distinguishing infected from noninfected abdominal fluid collections after surgery: An imaging, clinical, and laboratory-based scoring system. Invest Radiol, 2015; 50:17–23.
648.
NielsenJW, KurtovicKJ, KenneyBD, DiefenbachKA. Postoperative timing of computed tomography scans for abscess in pediatric appendicitis. J Surg Res, 2016; 200:1–7.
649.
SarkissianH, HymanN, OslerT. Postoperative fluid collections after colon resection: The utility of clinical assessment. Am J Surg, 2013; 206:551–554.
650.
McDermottFD, HeeneyA, KellyME, et al.Systematic review of preoperative, intraoperative and postoperative risk factors for colorectal anastomotic leaks. Br J Surg, 2015; 102:462–479.
651.
AntevilJL, EganJC, WoodburyRO, et al.Abdominal computed tomography for postoperative abscess: Is it useful during the first week?. J Gastrointest Surg, 2006; 10:901–905.
652.
van SantvoortHC, BesselinkMG, BakkerOJ, et al.A step-up approach or open necrosectomy for necrotizing pancreatitis. N Engl J Med, 2010; 362:1491–1502.
653.
Rangel-FraustoMS, PittetD, CostiganM, et al.The natural history of the systemic inflammatory response syndrome (SIRS). A prospective study. JAMA, 1995; 273:117–123.
654.
NivenDJ, LégerC, StelfoxHT, LauplandKB. Fever in the critically ill: A review of epidemiology, immunology, and management. J Intensive Care Med, 2012; 27:290–297.
655.
BouadmaL, LuytCE, TubachF, et al.Use of procalcitonin to reduce patients' exposure to antibiotics in intensive care units (PRORATA trial): A multicentre randomised controlled trial. Lancet, 2010; 375:463–474.
656.
MasedaE, Suarez-de-la-RicaA, AnilloV, et al.Procalcitonin-guided therapy may reduce length of antibiotic treatment in intensive care unit patients with secondary peritonitis: A multicenter retrospective study. J Crit Care, 2015; 30:537–542.
657.
NegmAA, PoosH, KruckE, et al.Microbiologic analysis of peri-pancreatic fluid collected during EUS in patients with pancreatitis: Impact on antibiotic therapy. Gastrointest Endosc, 2013; 78:303–311.
658.
van BaalMC, BollenTL, BakkerOJ, et al.The role of routine fine-needle aspiration in the diagnosis of infected necrotizing pancreatitis. Surgery, 2014; 155:442–448.
AndersenBR, KallehaveFL, AndersenHK. Antibiotics versus placebo for prevention of postoperative infection after appendicectomy. Cochrane Database Syst Rev, 2005; 3:CD001439.
661.
LeeSL, IslamS, CassidyLD, et al.Antibiotics and appendicitis in the pediatric population: an American Pediatric Surgical Association Outcomes and Clinical Trials Committee systematic review. J Pediatr Surg, 2010; 45:2181–2185.
662.
SirinekKR, LevineBA. A randomized trial of ticarcillin and clavulanate versus gentamicin and clindamycin in patients with complicated appendicitis. Surg Gynecol Obstet, 1991; 172 (Suppl):30–35.
663.
DoughertySH, SirinekKR, SchauerPR, et al.Ticarcillin/clavulanate compared with clindamycin/gentamicin (with or without ampicillin) for the treatment of intra-abdominal infections in pediatric and adult patients. Am Surg, 1995; 61:297–303.
664.
UhariM, SeppänenJ, HeikkinenE. Imipenem-cilastatin vs. tobramycin and metronidazole for appendicitis-related infections. Pediatr Infect Dis J, 1992; 11:445–450.
665.
AlloMD, BennionRS, KathirK, et al.Ticarcillin/clavulanate versus imipenem/cilistatin for the treatment of infections associated with gangrenous and perforated appendicitis. Am Surg, 1999; 65:99–104.
666.
BradleyJS, FaulknerKL, KlaugmanKP. Efficacy, safety and tolerability of meropenem as empiric antibiotic therapy in hospitalized pediatric patients. Pediatr Infect Dis J, 1996; 15:749–757.
667.
SchroppKP, KaplanS, GolladayES, et al.A randomized clinical trial of ampicillin, gentamicin and clindamycin versus cefotaxime and clindamycin in children with ruptured appendicitis. Surg Gynecol Obstet, 1991; 172:351–356.
668.
CiftciAO, TanyelFC, BüyükpamukçuN, HiçsönmezA. Comparative trial of four antibiotic combinations for perforated appendicitis in children. Eur J Surg, 1997; 163:591–596.
669.
AddersonEE, FlynnPM, HoffmanJM. Efficacy and safety of cefepime in pediatric patients: A systematic review and meta-analysis. J Pediatr, 2010; 157:490–495.
670.
StutmanHR. Clinical experience with aztreonam for treatment of infections in children. Rev Infect Dis, 1991; 13(Suppl 7):S582–S585.
671.
BurkhardtJE, HillMA, CarltonWW, KestersonJW. Histologic and histochemical changes in articular cartilages of immature beagle dogs dosed with difloxacin, a fluoroquinolone. Vet Pathol, 1990; 27:162–170.
672.
StahlmannR, KühnerS, ShakibaeiM, et al.Chondrotoxicity of ciprofloxacin in immature beagle dogs: Immunohistochemistry, electron microscopy and drug plasma concentrations. Arch Toxicol, 2000; 73:564–572.
673.
BradleyJS, BehrendtCE, ArrietaAC, et al.Convalescent phase outpatient parenteral antiinfective therapy for children with complicated appendicitis. Pediatr Infect Dis J, 2001; 20:19–24.
674.
NewmanN, WattadE, GreenbergD, et al.Community-acquired complicated intra-abdominal infections in children hospitalized during 1995–2004 at a paediatric surgery department. Scand J Infect Dis, 2009; 41:720–726.
675.
MellerJL, ReyesHM, LoeffDS, et al.One-drug versus two-drug antibiotic therapy in pediatric perforated appendicitis: A prospective randomized study. Surgery, 1991; 110:764–767.
676.
EmilS, TaylorM, NdiforchuF, NguyenN. What are the true advantages of a pediatric appendicitis clinical pathway?. Am Surg, 2006; 72:885–889.
677.
HenryMC, WalkerA, SilvermanBL, et al.Risk factors for the development of abdominal abscess following operation for perforated appendicitis in children: A multicenter case-control study. Arch Surg, 2007; 142:236–241.
678.
ShawyerAC, HatchellAC, PembertonJ, FlageoleH. Compliance with published recommendations for postoperative antibiotic management of children with appendicitis: A chart audit. J Pediatr Surg, 2015; 50:783–785.
679.
DobremezE, LavrandF, LefevreY, et al.Treatment of post-appendectomy intra-abdominal deep abscesses. Eur J Pediatr Surg, 2003; 13:393–397.
680.
GasiorAC, Marty KnottE, OstlieDJ, St. PeterSD. To drain or not to drain: An analysis of abscess drains in the treatment of appendicitis with abscess. Pediatr Surg Int, 2013; 29:455–458.
681.
RaoSC, BasaniL, SimmerK, et al.Peritoneal drainage versus laparotomy as initial surgical treatment for perforated necrotizing enterocolitis or spontaneous intestinal perforation in preterm low birth weight infants. Cochrane Database Syst Rev, 2011; 6:CD006182.
682.
MossRL, DimmittRA, BarnhartDC, et al.Laparotomy versus peritoneal drainage for necrotizing enterocolitis and perforation. N Engl J Med, 2006; 354:2225–2234.
683.
ReesCM, EatonS, KielyEM, et al.Peritoneal drainage or laparotomy for neonatal bowel perforation? A randomized controlled trial. Ann Surg, 2008; 248:44–51.
684.
TickellD, DukeT. Evidence behind the WHO guidelines: Hospital care for children: For young infants with suspected necrotizing enterocolitis (NEC), what is the effectiveness of different parenteral antibiotic regimens in preventing progression and sequelae?. J Trop Pediatr, 2010; 56:373–378.
685.
BrookI. Microbiology and management of neonatal necrotizing enterocolitis. Am J Perinatol, 2008; 25:111–118.
686.
ThompsonAM, BizzarroMJ. Necrotizing enterocolitis in newborns. Pathogenesis, prevention and management. Drugs, 2008; 68:1227–1238.
687.
ShahD, SinnJK. Antibiotic regimens for the empirical treatment of newborn infants with necrotising enterocolitis. Cochrane Database Syst Rev, 2012; 8:CD007448.
688.
ZaniA, EatonS, PuriP, et al.International survey on the management of necrotizing enterocolitis. Eur J Pediatr Surg, 2015; 25:27–33.
689.
SolomkinJS, RameshMK, CesnauskasG, et al.Phase 2, randomized, double-blind study of the efficacy and safety of two dose regimens of eravacycline versus ertapenem for adult community-acquired complicated intra-abdominal infections. Antimicrob Agents Chemother, 2014; 58:1847–1854.
690.
LucastiC, VasileL, SandescD, et al.Phase 2, dose-ranging study of relebactam with imipenem-cilastatin in subjects with complicated intra-abdominal infection. Antimicrob Agents Chemother, 2016; 60:6234–6243.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
